The power to react. The potential to grow.

In these uncertain times, consolidate your molecular testing today on a platform that offers scalability, growth and confidence for tomorrow.

VISIT THE HOLOGIC® VIRTUAL BOOTH TO LEARN MORE.

AVAILABLE TODAY

CT/NG
Mycoplasma genitalium
Trichomonas vaginalis
Bacterial vaginosis
Candida vaginitis/Trichomonas vaginalis
HSV 1 & 2

ADD ON

PANTHER®
ADD ON PANTHER FUSION®
ADD ON PANTHER PLUS
ADD ON PANTHER® LINK

HPV
HPV 16/18/45
Group B Strep
Zika Virus *
HIV-1 Quant
HIV-1 Qual Claim *
HCV Quant Dx
HBV Quant
CMV *
Flu A/B/RSV
Parafiu
AdV/hMPV/RV

SARS-CoV-2
SARS-CoV-2/Flu/A/B *
Bordetella *
GI Panel *

GROW ON PANTHER

COMING SOON

PANTHER® TRAX *

* In development and not for sale.
† Aptima Zika Virus assay:
• This test has not been FDA cleared or approved;
• This test has been authorized by FDA under an EUA for use by authorizedaries;
• This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and
• This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
‡ Seeking dual claim for the HIV-1 Quant assay.
§ The Aptima and Panther Fusion SARS-CoV-2 assays:
• These tests have not been FDA cleared or approved;
• These tests have been authorized by FDA under an EUA for use by authorized laboratories;
• These tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
• These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

ADS-03054-001 Rev. 001 © 2020 Hologic, Inc. All rights reserved. Hologic, Aptima, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Personal Genome Diagnostics (PGDx) is Empowering the Fight Against Cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and health economics by developing an innovative portfolio of regulated tissue-based and non-invasive liquid biopsy genomic based Next Generation Sequencing (NGS) products for laboratories worldwide.

We are placing the power of proximity in the hands of physicians and lab directors, and putting the power of control back into your patient care ecosystem.

Want to learn more about our products and partnerships, visit pgdx.com or call (443) 602-8833.
Break Through Your SARS-CoV-2 Testing Bottleneck

Secure a Reliable Supply of Testing Materials Under $10 Per Sample

SARS-CoV-2 Testing on the MassARRAY® System

→ Immediate availability of instruments and reagents
→ Mitigate supply chain risks with reliable supply
→ Test 1000s of samples per day on a single instrument
→ Perform testing at under $10 per sample

Alleviate testing material shortages with the MassARRAY® SARS-CoV-2 Panel. With a secure supply of instruments and reagents, Agena Bioscience® can help to quickly increase your SARS-CoV-2 testing capacity. Laboratories can process 1000s of samples in less than 24 hours on a single MassARRAY System, helping them keep pace with increased volumes.

Get Started Now
Ask us about our solutions for combined detection of Flu A/B and SARS-CoV-2.

Visit agenabio.com or call 1-858-882-2800

The assay is available for in vitro diagnostic use under the U.S. FDA’s Emergency Use Authorization and is CE-IVD marked in Europe.
Visit [keytruda.com/hcp](http://keytruda.com/hcp) to learn more about KEYTRUDA:

- Approved indications
- Resources for health care professionals
- The Merck Access Program
- KEY+YOU Support Program for patients
Table of Contents

General Information

Code of Conduct ................................................................................................................................. 7
Highlights & General Information ........................................................................................................ 9
Award for Excellence 2020 Recipient ............................................................................................... 12
Jeffrey A. Kant Leadership Award 2020 Recipient .......................................................................... 13
Meritorious Service Award 2020 Recipient ..................................................................................... 14
2020 Registration Support Award Recipients ...................................................................................... 15

Continuing Education

Continuing Education Information ...................................................................................................... 17
Continuing Education Tracker ......................................................................................................... 18

Program

Full Program Listing ......................................................................................................................... 21

Posters

Poster Information ............................................................................................................................. 51
Poster Listing .................................................................................................................................. 52
Author Index ................................................................................................................................... 73

Exhibits

Exhibitor Listing ............................................................................................................................. 86
Exhibitor Descriptions .................................................................................................................... 88

~~~
Virtual Meeting Code of Conduct

Policy:

The Association for Molecular Pathology (AMP) is committed to providing a friendly, comfortable, and welcoming virtual event environment for all, regardless of gender, sexual orientation, disability, race, ethnicity, religion, national origin, age, gender identity, or any other demographic group. We expect all attendees, media, speakers, AMP staff and volunteers, vendors/contractors, guests, and exhibitors to take an active role in providing a safe and positive experience for everyone by conducting themselves in a professional and lawful manner.

Unacceptable behavior can take many forms, including words, messages, posts within a virtual or social media platform, or actions. For example, intimidation, unwelcome sexual advances, or abusive or vulgar language. Such behavior from any participant in an AMP activity, attendees, users of online services, media, presenters, AMP staff and volunteers, vendors/contractors, guests, and exhibitors, will not be tolerated.

Anyone asked to stop unacceptable behavior is expected to comply immediately. If a participant is found to have engaged in unacceptable behavior, the AMP Executive Director will determine appropriate action to be taken, if any, which may include expulsion from the AMP activity, without refund, and/or contacting local law enforcement authorities. The Board of Directors may consider the matter for additional action.

While we cannot influence behavior outside of the virtual platform, we expect all participants at AMP virtual events and meetings to abide by this Code of Conduct in all venues, including whatever virtual platform being used, ancillary events and all social gatherings. All participants are responsible for their own conduct. Anyone who is the recipient of unacceptable behavior should feel free to speak up without any fear of retaliation.

Expected Behaviors

- AMP holds its collegial community in high value. Do your part to give everyone you encounter an enjoyable experience so they remember you and the meeting favorably.
- Exercise consideration and respect in your speech, written text and actions.
- Abstain from all demeaning, discriminatory, or harassing behavior and language when communicating with others.
- Respect the fact that slides and e-posters may include unpublished work so if a speaker or author requests that slides or posters not be “photographed,” do not download, take a screen shot, photograph or video your screen, or otherwise retain them.
- Do not video, audio, or otherwise record presentations.
- Slides and/or handouts available within the virtual platform may be downloaded for non-commercial use. Scientific integrity mandates that speakers and authors be acknowledged.
- Registrations are for individual access. Please do not share or broadcast the meeting to a group or share your platform login access with anyone else.
- Be mindful of your fellow participants. Alert the AMP Meetings Department at meetings@amp.org or at the Virtual Meeting Help Desk if you notice behavior that violates this Code of Conduct.
Unacceptable Behaviors

Unacceptable Behaviors at AMP Virtual Events Include:

- Intimidating, harassing, abusive, discriminatory, derogatory or demeaning speech, written text, or actions
- Harmful or prejudicial verbal or written comments, jokes, or visual images related to gender, sexual orientation, disability, race, ethnicity, religion, national origin, age, gender identity, or any other demographic group
- Use of provocative and/or sexual images, including in presentation slides, posts within a virtual or social media platform, and in exhibit booths
- Intimidation in any form, such as virtual stalking
- Unwelcome or uninvited attention or contact
- Real or implied threat of harm of any type, including physical, professional, or financial
- Retaining, by any means, slides, presentations, or posters when the presenter/author requests “no photography” or otherwise indicates this directive.
- Disruption of sessions or other events
- Failure to follow the directives of the session moderators or AMP staff

What To Do If You Observe or Experience Conduct That Violates this Code of Conduct:

- Anyone who is the recipient of unacceptable behavior should feel free to speak up without any fear of retaliation.
- Please contact the AMP Meetings Department at meetings@amp.org or at the Virtual Meeting Help Desk if you notice behavior that violates this Code of Conduct. All reports will be kept confidential to the extent possible while allowing for effective investigation and response.
- AMP Staff will help participants contact relevant authorities, and otherwise assist those experiencing conduct that violates this Code of Conduct. We value your participation with AMP, and want your experience to be professionally rewarding and personally enjoyable.
Highlights & General Information

For the most up to date information please visit:
https://amp20.amp.org/program/attendee-information/

General Information

- The **AMP Virtual Platform** will be accessible to registered meeting attendees **starting Monday, November 16, 2020 at 10:00 AM Eastern** through Monday, February 15, 2021 at 11:59 PM. *Note: You will NOT be able to login/access the event until that time.*
- The AMP virtual platform will give you access to scientific sessions, corporate workshops, eposters, the expo hall and several other exciting features!
- All sessions and events are listed in US Eastern time.
- Please make sure you login/logout each day so your account is updated with important announcements.
- Live Hours For Technical/Program Questions: Will be available for the following times, just email: amp20@getvfairs.io

<table>
<thead>
<tr>
<th>Days</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon</td>
<td>10am – 7pm</td>
</tr>
<tr>
<td>Tues</td>
<td>9am – 7pm</td>
</tr>
<tr>
<td>Wed</td>
<td>10am – 7pm</td>
</tr>
<tr>
<td>Thurs</td>
<td>10am – 7pm</td>
</tr>
<tr>
<td>Fri</td>
<td>10am – 5pm</td>
</tr>
</tbody>
</table>

Virtual Platform User Guides

Please refer to the following "User Guides" as you navigate your way through the virtual platform!

- Getting Started/Setting Up Your Profile
- Technical Support
- Scientific Sessions
- Corporate Workshop Theater
- Poster Hall
- Expo Hall
- Chat with Exhibitors
- Networking & Social Events
- Continuing Education
- AMP Leaderboard
- Expo Hall Scavenger Hunt

Program Information

The full scientific program can be found on the meeting [website](https://amp20.amp.org/program/attendee-information). Please be sure to check out all the areas of the virtual platform, including the Auditorium (scientific sessions), Poster Hall, Expo Hall, and Corporate Workshop Theater.

Continuing Education

Included in your attendee registration, you will be eligible to apply for continuing education credit! Unlike previous years, you will be able to apply for significantly more credits because you will...
have the ability to watch the sessions onDemand through February 15th! Please wait to submit for CE until you've watched all of the sessions for which you want to claim credit! Please click here for more information.

**Code of Conduct**

Please make sure you review [AMP's Code of Conduct](#).

**Social Media**

Follow AMP on Twitter, Facebook and LinkedIn, and use the #AMPPath20 and #AMPifier hashtags to join the conversation! We encourage you to share insights from the meeting, but ask that all attendees refrain from taking/sharing photos of slides or posters without permission. Please be respectful and courteous to your colleagues, and most importantly, have fun!

Social Media Guidelines

We encourage the use of social media for professional networking purposes before, during and after AMP 2020. To ensure that everyone has a positive social media experience, please adhere to these guidelines:

**Do:**

- Follow AMP on Twitter (@AMPath), like us on Facebook (facebook.com/AMPathology), and/or join our LinkedIn group (linkedin.com/groups/2681654)
- Use the #AMPPath20 hashtag to join the conversation and get the latest annual meeting updates
- Post about what you discover at the meeting, but be mindful of requests for confidentiality or attribution
- Share your knowledge and insights
- Be respectful and courteous to your colleagues
- Have fun!

**Don’t:**

- Post inflammatory, disrespectful or otherwise inappropriate comments
- Take/share photos of slides or posters without permission
- Post copyrighted/trademarked/embargoed materials

**AMP Central**

Visit AMP Central to view AMP Documents, access the Chat Rooms and be connected to AMP’s Social Media platforms.

**Expo Hall**

Be sure not to miss the Virtual Expo Hall - whether you're searching for the latest products and services, are just browsing, or want to connect with one of your current vendors, the AMP Expo Hall has it all! Once in the Virtual Platform, please enter the "Expo Hall". You'll be able to search the "exhibitor index" or scroll through to see booths from AMP Corporate Partners and exhibiting companies.

**DON’T MISS THESE EXCITING FEATURES OF THE VIRTUAL EXPO HALL:**

- Reserve you "Chat Slot" with Premium Exhibitors during the designated Expo Hall hours.
• Save exhibitor documents to your "Virtual Meeting Bag" and email them to yourself later.
• Participate in the "Scavenger Hunt" in the Expo Hall and the "AMP Leaderboard" throughout the virtual platform! We have some really cool prizes - check them out on the "Leaderboard" menu tab in the Lobby!

We have designated Expo Hall hours (schedule below), but please visit the hall throughout the day and connect with with all of our exhibitors!

**Monday, November 16, 2020**
10:30am - 11:15am
2:00pm - 3:00pm - includes demos & drawings

**Tuesday, November 17, 2020**
11:00am - 11:45am
2:00pm - 3:00pm - includes demos & drawings

**Wednesday, November 18, 2020**
11:00am - 11:45am
2:30pm - 3:30pm - includes demos & drawings

**Thursday, November 19, 2020**
11:00am - 11:45am
2:00pm - 3:00pm - includes demos & drawings

**Friday, November 20, 2020**
11:00am - 11:45am
2:30pm - 3:30pm - includes demos & drawings

**Thank You Sponsors!** Thank you to our exhibitors and sponsors for their support of the 2020 Annual Meeting & Expo! Click [here](#) to see the current listing of exhibitors & sponsors!

**Corporate Workshops**
Corporate Workshop Day has been re-imagined to better accommodate a virtual format. In the past, time constraints or flight schedules limited how many events you could attend. Now, with complimentary OnDemand access to recorded sessions through February 15, 2021 you can catch all of your “must-see” content on your schedule. Please view the [Corporate Workshop Program](#) and visit the Corporate Workshop Theater to view these workshops!

**Innovation Spotlights**
This year’s Innovation Spotlight Stages will include exhibitor spotlights as well as two presentations from AMP’s Training & Education Committee. You can view the Exhibitor Spotlight in the Corporate Workshop Theater and the Training & Education Committees presentations in the Auditorium. Schedules for this program are available on the website, please [click here](#) to view the schedule.

**Networking & Social Events**
Check out the [website](#) for information on some exciting networking events - including some of our favorites like the trainee and technologist mixers and the AMP Talent Show! Also, if you like beer and wine, please check out those social events as well!
ASSOCIATION FOR MOLECULAR PATHOLOGY

AMP Award for Excellence in Molecular Diagnostics 2020

Dennis Lo, FRS
The Chinese University of Hong Kong
ASSOCIATION FOR MOLECULAR PATHOLOGY

Jeffrey A. Kant Leadership Award 2020

For Exceptional Leadership in Advancing the Mission and Goals of the Association for Molecular Pathology

Karen P. Mann, MD, PhD
Grady Health System
Emory University School of Medicine
Atlanta, GA
ASSOCIATION FOR MOLECULAR PATHOLOGY

AMP Meritorious Service Award 2020

Ronald M. Przygodzki, MD
Department of Veterans Affairs, Veterans Health Administration, Office of Research & Development, Washington, DC
ASSOCIATION FOR MOLECULAR PATHOLOGY

Registration Support Awards 2020

Trainees

Sara Akhavanfard, MD, PhD - Nationwide Children's Hospital, Columbus, OH
Erica Kay Barnell - Washington University School of Medicine, Saint Louis, MO
Isabel Betancor Fernández - Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
Kelly E. Craven, MD, PhD - Johns Hopkins University School of Medicine, Baltimore, MD
Pratik Deb, MD, PhD - Rutgers New Jersey Medical School, Newark, NJ
Ryan DeCoste, MD - QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
Samreen Fathima, MD - Baylor University Medical Center, Dallas, TX
Matthew Gayhart, MD - Cedars-Sinai Medical Center, Los Angeles, CA
Lisa Lansdon, PhD - Children's Mercy Kansas City, Kansas City, MO
Cullen M. Lilley, MA - Loyola University Chicago Stritch School of Medicine, Maywood, IL
Andres G. Madrigal, MD, PhD - Oregon Health & Science University, Portland, OR
Marilena Melas, PhD - Institute for Genomic Medicine/ Nationwide Children's Hospital, Columbus, OH
Vamsi Parini - The Johns Hopkins University School of Medicine, Baltimore, MD
Vanessa Smith, MD - Duke University Health System, Durham, NC
Yian Wang - Coder School, Irvine, CA

Technologists

Ayah Abdulhamid - Children's Mercy Hospital, Kansas City, MO
Diana Gerrard - University of Vermont Medical Center, Burlington, VT
Egiebade Iriabho - The University of Alabama at Birmingham, Birmingham, AL
Krupa Jani - Memorial Sloan Kettering Cancer Center, New York, NY
Brittany Jones - St. Jude Children's Research Hospital, Memphis, TN
Julie Joyce - Children's Mercy Hospital, Kansas City, MO
Melissa Remmel - Inflammatix, Burlingame, CA
Jeffery Schubert - Children's Hospital of Philadelphia, Philadelphia, PA
Susan Shumaker - St. Jude Children's Research Hospital, Memphis, TN
Patricia L. Stow - St. Jude Children's Research Hospital, Memphis, TN
Rebecca Wallace - St. Jude Children's Research Hospital, Memphis, TN
ASSOCIATION FOR MOLECULAR PATHOLOGY

Registration Support Awards 2020

Individuals Underrepresented in Medicine

Adewole Adegboruwa, MS - Magnolia Diagnostics LLC, Dallas, TX
David O. Henriquez Ticas, MD - Baylor College of Medicine, Houston, TX
Patricia Hernandez, MD - Institute for Systems Biology, Tucson, AZ
Peter Louis, MD, JD, MT (ASCP) - Vanderbilt University Medical Center, Nashville, TN
Jude Noel, MS – Virginia Commonwealth University Health, Richmond, VA
Veronica Ortega, BS, BA – UTHouston, San Antonio, TX

Residents of Lower-middle- and Lower-income Countries

Zeeshan Ahmed, MBBS - Aga Khan University Hospital, Karachi, Pakistan
Vincent Francis P. Castillo, MD - St. Luke's Medical Center - Global City, Taguig City, Metro Manila, Philippines
Gauri Deshpande, MD - Tata Memorial Hospital, Mumbai, Maharashtra, India
Vivek Gupta, MD, PhD - Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India
Zahra Hasan, PhD - Aga Khan University, Karachi, Pakistan
Sawsan Ismail, MD - Tishreen University Hospital, Lattakia, Syria
Sudha S. Murthy, MD - Datar Cancer Genetics Ltd, Nashik, Maharashtra, India
Shano Naseem, MD - Postgraduate Institute of Medical Education and Research, Chandigarh, India
Ruhul Quddus, MBBS - Aga Khan University Hospital, Karachi, Pakistan
Continuing Education

Physicians

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Amedco LLC designates this live streamed activity for a maximum of 59.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CMLE

This activity has been planned and implemented in accordance with Amedco and the joint provider-ship of the ASC and the Association for Molecular Pathology (AMP) and has been approved for 59.50 Credits of CMLE Hours.

American Board of Pathology (ABPath) MOC

This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 13.00 credit hours. Participant information will be uploaded to the ABPath MOC Board 30 days post activity.

*IMPORTANT: The ABPath MOC/SAM Program will end 12/31/2020. All credits must be claimed by that date.

For any questions, contact ampeducation@amp.org.
<table>
<thead>
<tr>
<th>Session Date</th>
<th>Session Title</th>
<th>Faculty</th>
<th>CME/ME Eligible Hour (Available through 2/15/21)</th>
<th>SAMs Eligible Hour (Available through 12/31/2020)</th>
<th>Number of hours attended of session</th>
<th>Session Notes and Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday November 16</td>
<td>AMP Award for Excellence in Molecular Diagnostics: Presentation and Lecture</td>
<td>Dennis Lo, FRS</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Molecular Methods for Discovery of Novel Pathogens</td>
<td>Ian Schwartz, MD, PhD and Lea Stanila</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reengineering to hg38</td>
<td>Justin Zhou, PhD and Sabia Kaddi, PhD</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Integrative Analysis of the Tumor Microenvironment</td>
<td>Thomas Gajewski, MD, PhD and Scott Rodig, MD</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeted Therapies for Constitutional Genetic Diseases</td>
<td>Garry Cutting, MD</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case Studies in Infectious Diseases and Solid Tumors</td>
<td>Eun Kim, MSC; Debbie Walley, MD; William Webber, DO; Adam Rich, MD, PhD; and Matthew Gayhart, MD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implementation of Molecular Infectious Diagnostics Test at the Point-of-Care</td>
<td>Omai Gamed, PhD and Raquel M. Martinez, MBA, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Laboratory Assurance Compliance Solutions</td>
<td>Justin Hammersing, MBA</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case Studies in Hematopathology and Solid Tumors</td>
<td>Jessica Dernia, MD, Jonathan Tai, MD, PhD; Sara Alkhawafard, MD, PhD; and Eric Good, MD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epigenetics In Malignant Hematology</td>
<td>Maria Figuera, MD</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday November 17</td>
<td>Single-Cell Insights into Myeloid Neoplasia</td>
<td>Kochi Takahashi, MD, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Platform Presentations of Selected Genetic’s Abstracts</td>
<td>Elon Hahn, MD; Diana Mandelker, MD, PhD; Gage Gaylor-Binoy, PhD; and Dale Mucose, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Platform Presentations of Selected Hematopathology Abstracts</td>
<td>Elan Haque-Stroemburg, MD, PhD; Miguel Cantu, MD; Mia Donna Dalebrook, MT(ASCP); and Lu Wang, MD, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Platform Presentations of Selected Infectious Diseases Abstracts</td>
<td>Michael Tomasz, Priya Veros, MD, PhD; Rosie Kenery, PhD; and Timothy Beunlauf, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Practical Approaches to Diagnostic Stewardship of Advanced Molecular Tests</td>
<td>Dani Deckman, MD, Neil Anderson MD, Amanda Hamilton, PhD, and D. Jane Hara, MD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Single-cell Sequencing/Single-Seq: A scalable Method for Spatially Resolved Gene Expression Studies</td>
<td>Chi Rosenthal-Rosen, PhD</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case Studies in Genetics and Hematopathology</td>
<td>Kelly Kohler, PhD; MS; Danita Toledo, MD, PhD; Sajjal Ahmad, MSc; Maridena Mota, MSc; and Won Sok Lee, MD, MPH</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next-generation Sequencing Assay Development and Validation</td>
<td>Ryma Benayed, PhD, Eric Konnick, MD; MS; Kut Davies, PhD; Dana Alper, MD, PhD, and Jeremy Sepul, MD, PhD</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variant Review and Classification Workshop</td>
<td>Laura Taffe, MD; Somaik Roy, MD; Mark Noulburt, MD, PhD</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Date</td>
<td>Session Title</td>
<td>Faculty</td>
<td>CME/CME Eligible Hours (Available through 2/15/21)</td>
<td>SAMs Eligible Hours (Available through 12/31/2020)</td>
<td>Number of hours attended</td>
<td>Session Notes and Comments</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>--------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Tuesday November 17</td>
<td>High-Throughput Functional and Genomic Approaches for Understanding Genome and Somatic</td>
<td>Colin Teshima, PhD and Jay Shendure, MD, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tuesday November 17</td>
<td>COVID-19 Molecular Testing: Experiences from the Field</td>
<td>Teresa Kame, MD, Anthony Yan, MPH, Beth Maxwell, PhD, Michael Bariman, MD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tuesday November 17</td>
<td>Laboratory Economics During a Public Health Emergency: Lessons Learned (and still learning) from the Field</td>
<td>Elisa Miller, J.D, Samuel Caugant, MD, Pauli Chandola, DO, and Jey Patel, MD, MBA</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wednesday November 18</td>
<td>Coronaviruses: Pandemic Updates</td>
<td>Carlos del Rio, MD</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wednesday November 18</td>
<td>Distributed Laboratories and Their Path Interpretation Services</td>
<td>Gar-Ji Gao, MD, PhD, Matthew Leibo, MD, and Rakish Nagarejan, MD, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wednesday November 18</td>
<td>Clinical Metagenomics Is Worth the Juice</td>
<td>Steve Miller, MD, PhD, William Muller, MD, PhD, Stephanie Mitchell, PhD, and Debbie Paladiz, MD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wednesday November 18</td>
<td>Early Detection and Characterization of Cancer using ctDNA and Distinction from the Field</td>
<td>Pedram Razavi, MD, PhD and Victor Valicenco, MD, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Wednesday November 18</td>
<td>Bridging the Gap: Molecular Tumor Boards, Clinical Trial Matching, and the Future</td>
<td>Martes Garcia-Kuins, MD, PhD, and Mia Levy, MD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Machine Learning in Health Care</td>
<td>Stephen Kingsmore, MD, DSc</td>
<td>1.0</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Platform Presentations of Selected Informatics Abstracts</td>
<td>Jagadeeshwar Balan, Andrew Stol, PhD, Andrea Borer, PhD, and Epiabdele Habibe, MSc</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Platform Presentations of Selected Solid Tumor Abstracts</td>
<td>Cameron Biech, MD, Ryan DeCra, MD, Fumin Lu, PhD, and Eliza Barnell, PhD</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Platform Presentations of Selected Technical Topics Abstracts</td>
<td>Nuoiam Wang, MD, Chak Karvuch, PhD, Lei Zhang, and Emerd Larm</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>True or False: Interpretation Challenges of Blood Culture Identification</td>
<td>Richard Davis, PhD, and Suam Bullen-Mo, PhD</td>
<td>1.0</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Addressing the Clinical Laboratory Workforce Shortage - Automation and Robotics</td>
<td>Jose Manuel Collados, ABd and Susanne Morikanto</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Next-generation Sequencing Away Development and Validation Q&amp;A</td>
<td>Dana Avare, MD, PhD, Pynna Benayad, MD, Kurt Davies, MD, Eric Kermick, MD, MS, and Jeremy Segal, MD, PhD</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Tissue Stewardship: Maximizing the Information That Can Be Provided by Small Tissue Biobanks</td>
<td>Sincia Roy Chowdhuri, MD, PhD, and Christopher Gilbert, DD</td>
<td>1.0</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Next Generation Guidelines for Clinical Sequencing: Translating Regulations into Practice</td>
<td>Riggi Funte, PhD and Annetta Leon, PhD, MS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>What Do All These Mutations Mean?</td>
<td>Kelly Bolton, MD, PhD and Amy Deaem, MD, MS</td>
<td>1.5</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Genomics in Childhood: Coming of Age</td>
<td>Sharon Ron, MD, PhD and Jinghui Zhang, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>Enhanced Molecular Diagnosis through Structural Variant Detection</td>
<td>Madhu Hegde, PhD, Stephen Lincoln and Nicole Hoppman, PhD</td>
<td>1.5</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>The Roadmap to Recognition of Molecular Professionals as Qualified Healthcare</td>
<td>Charles Matthews, MPH, Anilea Femina-Gonzales, PhD, Elaine Lyon, PhD, Tina Luckwood, PhD, and John Schotel, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thursday November 19</td>
<td>SNP Typing in Clinical and Public Health Laboratory: Migration to Whole Genome</td>
<td>William Glover, PhD and Sanchita Das, MD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Friday November 20</td>
<td>DelpHiT: The Cancer Dependency Map Project</td>
<td>William Hahn, MD, PhD</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Friday November 20</td>
<td>Genomics-Informed Lymphoma Classification</td>
<td>Sandeep Dave, MD and Javeed Iqbal, MS, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Session Date</td>
<td>Session Title</td>
<td>Faculty</td>
<td>CME/CME Eligible Hours (Available through 2/15/21)</td>
<td>SAAs Eligible Hours (Available through 12/31/2020)</td>
<td>Number of hours attended of session</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Friday November 20</td>
<td>Whole Genome Sequencing for Antimicrobial Resistance Testing</td>
<td>Matthew Binnicker, PhD and Kimberlee Musser, PhD</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>1:00pm - 2:30pm</td>
<td>Emerging Testing Paradigms and Insights</td>
<td>Steven Bleyl, MD, PhD, Scott Topper, PhD, James Lu, PhD</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Friday November 20</td>
<td>Tumor Evolution and Therapeutic Resistance</td>
<td>Noam Auslander, PhD and Peter Van Loo, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>1:00pm - 3:30pm</td>
<td>Next Generation Data: Integration and Dissemination of Molecular Pathology</td>
<td>Ahmet Zehir, PhD and Cihan Kaya, PhD</td>
<td>1.5</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Friday November 20</td>
<td>Gene Therapy for Retinal Disorders</td>
<td>Elia I. Traboulsi, MD</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>3:30pm - 4:30pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL HOURS</strong></td>
<td><strong>59.5</strong></td>
<td></td>
<td></td>
<td><strong>13.0</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Award for Excellence Lecture

Monday, November 16, 11:30 am – 1:00 pm

Session Type: Live
CE Credit: 1.5

Award for Excellence Lecture: Plasma DNA Based Molecular Diagnostics - From Dream to Reality
Dennis Lo, FRS, The Chinese University of Hong Kong, Hong Kong, China

Session Description: In this lecture, Dennis Lo will share with the audience regarding his journey from the discovery of fetal DNA in maternal plasma to the development of non-invasive prenatal testing (NIPT). He will also discuss the application of plasma DNA analysis to early cancer detection. Finally, he will discuss recent understanding of the biology of circulating DNA in blood.

Session Objectives:
• To appreciate the basic biology of circulating DNA in plasma.
• To obtain an overview of the clinical applications of noninvasive prenatal testing (NIPT).
• To obtain some insight about the use of liquid biopsies for cancer screening.

Case Studies in Infectious Diseases and Solid Tumors

Monday, November 16, 1:00 pm – 2:00 pm

Session Type: On Demand
CE Credit: 1
Path: Infectious Diseases, Oncology
Moderators: Erin H. Graf, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA and Christian Kunder, MD, PhD, Stanford University, Stanford, CA, USA

Molecular Characterization of Aspergillus Fumigatus by Next-generation Sequencing in Neonates Diagnosed with Invasive Fungal Dermatitis at a Tertiary Care Hospital – Florida, 2019
Eun a Kim, MSc, IDbyDNA, Draper, UT, USA

SARS-CoV-2 and Cytomegalovirus Co-infection in Patients Over 45: A Case Series
Debbie Rigney Walley, MD, Houston Methodist Hospital, Houston, TX, USA

Disseminated Histoplasmosis with Concomitant Mycobacterium Haemophilum and Anncailla Algerae Myositis in a Polymyositis Patient: A Diagnostic Approach
William Webster, DO, University of South Carolina School of Medicine-Prisma Health, Columbia, SC, USA

Papillary Thyroid Carcinoma with Hashimoto Thyroiditis: Detecting the Driver Signal in the Inflammatory Noise
Adam Fisch, MD, PhD, Massachusetts General Hospital, Boston, MA, USA
Next Generation Sequencing Catches a Cytopathology Pitfall
Matthew Gayhart, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:
• Describe the context of a challenging clinical case.
• Discuss the molecular pathology techniques used in the diagnosis of the case.
• Propose a final diagnosis based upon findings and diagnostic evidence.

Integrative Analysis of the Tumor Microenvironment
Monday, November 16, 1:00 pm – 2:00 pm

Session Type: Live
CE Credit: 1 | SAM: 1
Path: Oncology
Moderator: Raj Emmadi, MD, University of Illinois, Chicago, IL, USA

Integrative Analysis of the Tumor Microenvironment
Thomas Gajewski, MD, PhD, The University of Chicago, Chicago, IL, USA

Immune Cell Characterization via Multiplexed Digital Imaging
Scott Rodig, MD, PhD, Brigham and Women’s Hospital, Boston, MA, USA

Session Description: The rapidly expanding use of immunotherapy has significantly altered the landscape of cancer therapeutics. However, as our understanding of the tumor immune microenvironment grows, it is increasingly likely that multimodal interrogation of this environment will be needed to guide optimal therapeutic selection. This session will explore how current and emerging novel methods are expanding our knowledge of how tumor cells restructure their microenvironment to avoid immune attacks and how we can diagnose the alterations of the tumor-immune system interactions to implement precision medicine.

Session Objectives:
• Learn how state-of-art multiplex immunostaining, digital imaging, and computational algorithms can define and quantify anti-tumor immunity in a spatially-resolved manner in situ.
• Diagnose how the tumor-immune system interaction has broken down, so we can choose the proper interaction to fix it.

Molecular Methods for Discovery of Novel Pathogens
Monday, November 16, 1:00 pm – 2:00 pm

Session Type: Live
CE Credit: 1
Path: Infectious Diseases, Molecular Methodologies & Technologies
Moderator: Esther Babady, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The Use of Molecular Tests in the Discovery and Characterization of Emerging Fungal Pathogens
Ilan Schwartz, MD PhD, University of Alberta, Edmonton, Alberta, Canada
Molecular Methods for Discovery of Novel Pathogens
Lea M. Starita, PhD, University of Washington, Seattle, WA, USA

Session Description: Describe and discuss the use of novel and established molecular methods for the discovery of new pathogens of clinical importance.

Session Objectives:
• Discuss the use of molecular tests for discovery of new fungal pathogens.
• Discuss the use of molecular tests for discovery of new vector-borne pathogens.

Targeted Therapies for Constitutional Genetic Disorders
Monday, November 16, 1:00 pm – 2:00 pm

Session Type: Live
CE Credit: 1 | SAM: 1
Path: Inherited Conditions
Moderator: Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA

Molecular Therapies for Cystic Fibrosis
Garry Cutting, MD, Johns Hopkins University, Baltimore, MD, USA

Session Description: In the last several years, there have been significant advances in the area of targeted therapies for constitutional genetic disorders. This session will review the targeted molecular therapies for cystic fibrosis, their mechanisms of action, and their impact on patient care.

Session Objectives:
• Upon completion, participant will be able to describe novel targeted therapies for various genetic disorders.
• Upon completion, participant will be able to describe the mechanisms of targeted therapies and patient prognosis.

Transitioning to hg38
Monday, November 16, 1:00 pm – 2:00 pm

Session Type: Live
CE Credit: 1 | SAM: 1
Path: Informatics
Moderator: Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA

GRCh38/hg38 and Transitioning to hg38
Justin M. Zook, PhD, National Inst of Standards & Tech, Gaithersburg, MD, USA

Look Before You Leap: How to Systematically Move Clinical Diagnostic Testing from hg19 to hg38
Sabah Kadri, PhD, Lurie Children’s Hospital of Chicago, Chicago, IL, USA

Session Description: Human genome reference GRCh38 (hg38) has been around for years but its implementation into existing NGS assays has been very slow due to various reasons. This session aims to discuss the main differences between hg19 and hg38, and identify the challenges in transitioning into hg38 in clinical NGS assays.
Session Objectives:
• Describe the main differences between hg19 and hg38.
• Describe various of effects of moving a clinical NGS assay from hg19 to hg38 at various levels of test design and implementation.
• Define the effects of genome assembly change at sequence level, gene annotation level and variant annotation level.

Interactive Expo Hall with Demos and Drawings
Monday, November 16, 2:00 pm – 3:00 pm

Chat Room Discussion – Meet a Membership Affairs Committee (MAC) Member
Monday, November 16, 2:30 pm – 3:00 pm

Case Studies in Hematopathology and Solid Tumors
Monday, November 16, 3:00 pm – 4:00 pm

Session Type: On Demand
CE Credit: 1
Path: Oncology
Moderators: Kristin Hunt Karner, MD, Department of Pathology, University of Utah, Salt Lake City, UT, USA and Christian Kunder, MD, PhD, Stanford University, Stanford, CA, USA

Recurrent Mediastinal Neoplasm of Unknown Origin
Jessica B. Ziemba, MD, Beth Israel Deaconess Medical Center, West Roxbury, MA, USA

Fortuitous Detection of a NUP214-ABL1 Fusion Through Copy Number Changes
Jonathan M. Tsai, MD, PhD, Brigham and Women's Hospital, Brookline, MA, USA

Targeted RNA Sequencing Reveals a Cryptic t(9;11) Leading to KMT2A-MLLT3 Fusion in Accelerated Phase Primary Myelofibrosis Evolving into Acute Myeloid Leukemia
Audrey N. Jajosky, MD, PhD, University of Michigan, Cleveland, OH, USA

Undifferentiated Neuroblastoma with Unique Molecular Features
Sara Akhavanfard, MD, PhD, Nationwide Children’s Hospital, Beachwood, OH, USA

A Compound EGFR Exon 21 Mutation in a Metastatic Liver Mass
Eric A. Goold, MD, University of Utah/ARUP laboratories, Salt Lake City, UT, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case’s clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:
• Describe the context of a challenging clinical case.
• Discuss the molecular pathology techniques used in the diagnosis of the case.
• Propose a final diagnosis based upon findings and diagnostic evidence.
**Epigenetics in Malignant Hematology**  
Monday, November 16, 3:00 pm – 4:00 pm

**Session Type:** On Demand  
**CE Credit:** 1 | **SAM:** 1  
**Path:** Oncology  
**Moderator:** Noah Brown, MD, University of Michigan, Ann Arbor, MI, USA

**Epigenetics in Malignant Hematology**  
Maria E. Figueroa, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA

**Session Description:** In this session we will review how epigenetic deregulation contributes to the development of hematological malignancies, with a focus on myeloid malignancies.

**Session Objectives:**  
• To recognize epigenetic modifiers that contribute to malignant transformation.  
• To recognize the amplifying effect of epigenetic mutations by reprogramming the epigenome.

---

**Guidance for Reevaluation and Reanalysis of Genomic Test Results**  
Monday, November 16, 3:00 pm – 4:00 pm

**Session Type:** Live  
**CE Credit:** 1  
**Path:** Inherited Conditions  
**Moderator:** Ryan Schmidt, MD, PhD, Children's Hospital Los Angeles, Los Angeles, CA, USA

**Guidance for Reevaluation and Reanalysis of Genomic Test Results**  
Josh Deignan, PhD, University of California - Los Angeles, Los Angeles, CA, USA

**Session Description:** The evidence supporting the classification of variants detected during genomic testing, such as exome sequencing, is constantly accumulating. Additionally, new patient phenotypes may be recognized that impact variant interpretation. Thus, the diagnostic yield of genomic testing may be increased by reevaluation of variant classifications or case-level reanalysis. This session will provide guidance for laboratories seeking to perform reanalysis of genomic testing results.

**Session Objectives:**  
• Recognize the considerations surrounding the reevaluation and reanalysis of genomic test results.  
• Design and implement strategies for the reevaluation and reanalysis of genomic test results.

---

**Implementation of Molecular Infectious Diagnostic Tests at the Point-of-Care**  
Monday, November 16, 3:00 pm – 4:00 pm
Session Type: Live
CE Credit: 1
Path: Infectious Diseases, Lab Management
Moderator: Erin McElvania, PhD, NorthShore University HealthSystem, Evanston, IL, USA

**Triumphs and Challenges Surrounding Implementation of Point-of-care Molecular Assays Outside of the Microbiology Laboratory**
Omai Garner, PhD, UCLA, Los Angeles, CA, USA

**Implementation of Molecular Infectious Diagnostic Tests at the Point-of-Care**
Raquel M. Martinez, MBA, PhD, Geisinger, Danville, PA, USA

**Session Description:** Describe and discuss approaches to successful implementation of molecular infectious disease tests at the point-of-care (e.g. emergency room or outpatient laboratories).

**Session Objectives:**
• Discuss challenges in implementation of molecular identification testing at the point-of-care.
• Discuss triumphs in implementation of molecular identification testing at the point-of-care.

---

**Laboratory Assurance Compliance Solutions**
Monday, November 16, 3:00 pm – 4:00 pm

Session Type: Live
CE Credit: 1
Path: Molecular Methodologies & Technologies
Moderator: Jennifer Bergendahl, MT(ASCP), Michigan Medicine, Northville, MI, USA

**Digital Transformation: What Does It Mean for Compliance?**
Justin Hammerling, M.B.A., Kapios Health, Toledo, OH, USA

**Session Description:** Introduction to a compliance solution for clinical laboratories. Laboratory Assured Compliance Solutions (LACS) replaces paper logs in clinical laboratories with tablets to track scheduled instrument activity and notifies technologists with a chain of alerts until a required task is completed. LACS provides a centralized database to record and review equipment status, access records and run audit reports, all in real-time. Learn about a solution that was created in a laboratory just like yours, by people who really know the pains of regulatory audit obligations.

**Session Objectives:**
• Learn the benefits of Laboratory Assured Compliance Solutions (LACS).
• Gain an understanding of the platform that provides a centralized database to record and review equipment status, access records, and run audit reports, all in real-time.

---

**Corporate Workshops**
Monday, November 16, 4:00 pm – 5:00 pm

**Trainee Virtual Happy Hour & Mixer**
Monday, November 16, 5:00 pm – 5:45 pm
Social Event – Beer Tasting Event
Monday, November 16, 5:45 pm – 6:30 pm

Interactive Expo Hall
Tuesday, November 17, 11:00 am – 11:45 am

Chat with the 2020 Program Chair (Dr. Jane Gibson) & the 2021 Program Chair (Dr. Laura Tafe)
Tuesday, November 17, 11:45 am – 12:00 pm

Single Cell Insights into Myeloid Neoplasia
Tuesday, November 17, 12:00 pm – 1:00 pm

Session Type: Live
CE Credit: 1
Path: Oncology
Moderator: Noah Brown, MD, University of Michigan, Ann Arbor, MI, USA

Clonal Heterogeneity and Evolution of Myeloid Neoplasia with Single-cell Genomics
Koichi Takahashi, MD, PhD, UT MD Anderson Cancer Center, Houston, TX, USA

Session Description: The session will cover the recent updates on how single-cell genomics is unveiling the clonal heterogeneity of myeloid neoplasia and how this information can guide clinical decisions.

Session Objectives:
- Understand the technology and potential uses of single cell sequencing.
- Understand current findings from single cells sequencing in myeloid neoplasms and their implications for how myeloid neoplasms first arise, how they involve and the potential implications for patient management.

Platform Presentations of Selected Genetics Abstracts
Tuesday, November 17, 1:00 pm – 2:00 pm

Session Type: On Demand
CE Credit: 1
Path: Inherited Conditions
Moderators: Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA and Ryan Schmidt, MD, PhD, Children's Hospital Los Angeles, Los Angeles, CA, USA

Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to “chat” with the authors, please do so during the designated poster times in the Poster Hall.

- Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
- Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

G02 - Copy Number Variant Analysis Improves the Diagnostic Yield in a Cohort of Pediatric Patients with Previously Negative Constitutional Exome Sequencing Results
Elan Hahn, MD, University of Toronto, Toronto, Ontario, Canada

G11 - Mosaicism in Cancer Susceptibility Genes in Unselected Cancer Patients
Diana Mandelker, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Session Description: Platform presentations of selected Genetics abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Genetics Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Platform Presentations of Selected Hematopathology Abstracts
Tuesday, November 17, 1:00 pm – 2:00 pm

Session Type: On Demand
CE Credit: 1
Path: Oncology
Moderator: Noah Brown, MD, University of Michigan, Ann Arbor, MI, USA
Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to "chat" with the authors, please do so during the designated poster times in the Poster Hall.
• Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
• Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

H14 - Cloneretriever: An Automated Algorithm to Identify Clonal Immunoglobulin Gene Rearrangements by Next-generation Sequencing
Eitan Halper-Stromberg, MD PhD, JHU, Baltimore, MD, USA

H21 - Validation of MYD88 L265P Ddpcr Assay and Application in Assessment of Primary CNS Lymphoproliferative Disorders
Miguel D. Cantu, MD, New York Presbyterian-Weill Cornell, New York, NY, USA

H28 - Chromosome Arm Gain or Loss by Next Generation Sequencing
Mia Donna Dabrowski, MT(ASCP), AdventHealth Orlando, Orlando, FL, USA

H44- Comparison of Whole Genome Sequencing (WGS) with Conventional Cytogenetics in Profiling Genome-Wide Large-Scale Copy Number and Structural Variations in Pediatric and Adolescent AML
Lu Wang, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN, USA

Session Description: Platform presentations of selected Hematopathology abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Hematopathology Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Platform Presentations of Selected Infectious Diseases Abstracts
Tuesday, November 17, 1:00 pm – 2:00 pm
Session Type: On Demand
CE Credit: 1
Path: Infectious Diseases
Moderator: Esther Babady, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to “chat” with the authors, please do so during the designated poster times in the Poster Hall.

- Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
- Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

ID07 - Evaluation of an automated rRNA quantitation system for rapid AST in clinical lab diagnostics
Dakai Liu, PhD, NewYork-Presbyterian Queens Hospital, Flushing, NY, USA

ID27 - Evaluating the Clinical Utility of Next-Generation Sequencing of Nasopharyngeal Specimens for SARS-CoV-2 in the COVID-19 Pandemic
Priya Velu, MD, PhD, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA

ID52 - Design and Optimization of Novel ITS2-28s rRNA Gene Primers for Fungal Species Detection from Formalin-Fixed Paraffin-Embedded Tissues with a Targeted Next-Generation Sequencing Assay
Rossio K. Kersey, PhD, Joint Pathology Center, Bethesda, MD, USA

ID53 - Non-invasive Microbial Cell-free DNA Sequencing Detects Invasive Mold Infections in Immunocompromised Patients with Pneumonia
Tim Blauwkamp, PhD, Karius, Inc., Redwood City, CA, USA

Session Description: Platform presentations of selected Infectious Diseases abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Infectious Diseases Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Interactive Expo Hall with Demos and Drawings
Tuesday, November 17, 2:00 pm – 3:00 pm

Chat Room Discussion - Meet a Membership Affairs Committee (MAC) Member
Tuesday, November 17, 2:30 pm – 3:00 pm

Case Studies in Genetics and Hematopathology
Tuesday, November 17, 3:00 pm – 4:00 pm

Session Type: On Demand
CE Credit: 1
Path: Inherited Conditions, Oncology
Moderators: Alanna J. Church, MD, Boston Children's Hospital, Boston, MA, USA and Kristin Hunt Karner, MD, Department of Pathology, University of Utah, Salt Lake City, UT, USA
Persistent High Levels of Donor Cells Following Solid Organ Transplant Confirm Diagnosis of Graft versus Host Disease
Kelly A. Rafferty, PhD, MS, Virginia Commonwealth University, Richmond, VA, USA

Co-occurrence of Mosaic Turner Syndrome and Mosaic Spinal Muscular Atrophy Carrier Status in an Adult Female
Diana M. Toledo, PhD, MS, CGC, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

A Rare Occurrence of Three Compound Heterogeneous Mutations of HBB Gene Leading to B-thalassemia Major in a Pakistani Family
Sjjawal Ahmad, Msc, Aga Khan University, Hospital Pakistan, Karachi, Pakistan

When Old Meets New: Sophisticated Interplay of Multiple Technologies to Diagnose a Case of SOPH Syndrome
Marilena Melas, MSc, PhD, The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA

Identification of Targetable NUP214-ABL1 Fusion in T-lymphoblastic Leukemia
Won Sok Lee, MD, Virginia Commonwealth University, Richmond, VA, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:
• Describe the context of a challenging clinical case.
• Discuss the molecular pathology techniques used in the diagnosis of the case.
• Propose a final diagnosis based upon findings and diagnostic evidence.

Moving Towards Clinical-grade HGVS Nomenclature

Tuesday, November 17, 3:00 pm – 4:00 pm

Session Type: On Demand
CE Credit: 1
Path: Inherited Conditions
Moderator: Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA

Moving Towards Clinical-grade HGVS Nomenclature
Birgit Funke, PhD, FACMG, Sema4, Newton, MA, USA
Reece Hart, PhD, Reece Hart Consulting, San Francisco, CA, USA
Somak Roy, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Ryan Schmidt, MD, PhD, Children's Hospital Los Angeles, Los Angeles, CA, USA

Session Description: HGVS nomenclature is an essential vocabulary that allows for consistent description of sequence variants. However, HGVS nomenclature usage is highly variable across laboratories in proficiency testing surveys, and different software annotation tools frequently generate discordant HGVS nomenclature outputs. This session seeks to engage the diagnostic testing community in order to improve the consistency of HGVS nomenclature usage. Ongoing work by the CAP Genomic Medicine Committee on this topic will be presented.
Session Objectives:
• Identify sources of discrepancy in the usage of HGVS nomenclature.
• Compare potential solutions for improving the usage of HGVS nomenclature by laboratories.

Practical Approaches to Diagnostic Stewardship of Advanced Molecular Tests
Tuesday, November 17, 3:00 pm – 4:00 pm

Session Type: Live
CE Credit: 1
Path: Infectious Diseases
Moderator: Frederick S. Nolte, PhD, Medical Univ of South Carolina, Charleston, SC, USA

Practical Approaches to Diagnostic Stewardship of Advanced Molecular Tests
Neil Anderson, MD, Washington University in St. Louis, Saint Louis, MO, USA
Daniel Diekema, MD, MS, University of Iowa, Iowa City, IO, USA
Amanda Harrington, PhD, D(ABMM), Loyola University Medical Center, Maywood, IL, USA
D. Jane Hata, PhD, Mayo Clinic Florida, Jacksonville, FL, USA

Session Description: In a round table/panel format, describe and discuss various approaches taken by laboratory to ensure best utilization by clinicians, of advanced molecular testing, particularly as it applies to next generation, metagenomics sequencing for infectious disease diagnosis.

Session Objectives:
• Identify challenging areas that can benefit from diagnostic stewardship.
• Describe real world approaches that have been implemented to direct appropriate laboratory testing.
• Discuss the effectiveness of different diagnostic stewardship approaches.

SHORT COURSE: Next-generation Sequencing Assay Development and Validation
Tuesday, November 17, 3:00 pm – 6:00 pm

Session Type: On Demand
CE Credit: 3
Path: Informatics, Molecular Methodologies & Technologies
Moderator: Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA

Targeted Molecular Profiling using NGS Based Assays: A Clinical Journey
Ryma Benayed, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Amplicon NGS Sequencing – Considerations and Applications
Eric Konnick, MD, MS, University of Washington Department of Laboratory Medicine and Pathology, Seattle, WA, USA

RNA-Based NGS: Technical Considerations for Assay Validation
Kurtis Davies, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Nuts and Bolts: Details about NGS that You Need to Know  
Dara Aisner, MD, PhD, University of Colorado Hospital, Aurora, CO, USA

Bioinformatics Pipeline Development for NGS Oncology Laboratory Developed Tests  
Jeremy Segal, MD, PhD, University of Chicago, Chicago, IL, USA

Session Description:  NGS-based genomic assays continue to evolve regarding methodologies and clinical applications. This short course from experts in genomic diagnostics aims to provide practical guidelines on the different aspects of designing NGS assays including assay design principles, wet-bench validation, and bioinformatics validation and implementation. Speakers will be available at a 1 hr live Q&A session for an interactive discussion.

Session Objectives:
• Describe best practices for designing panels for DNA and RNA sequencing applications.
• Recognize steps in designing and implementing bioinformatics pipelines from aligning sequencing reads to detecting various genomic alterations.
• List the principles of validation and implementation of NGS based assays.

Single-cell Sequencing  
Tuesday, November 17, 3:00 pm – 4:00 pm

Session Type: Live  
CE Credit: 1  
Path: Molecular Methodologies & Technologies, Oncology  
Moderator: Renee Webb, BS, MT (ASCP), Texas Children's Hospital, Houston, TX, USA

Cell Atlases as Roadmaps to Understand and Treat Disease  
Orit Rozenblatt-Rosen, PhD, Broad Institute, Cambridge, MA, USA

Session Description: Cells are the basic unit of life, yet we know surprisingly little about them. They vary immensely within the body, and express different sets of genes. Without maps of different cell types and where they are located in the body, we cannot describe all their functions and understand the biological networks that direct their activities. Recent advances in single-cell genomic analysis of cells and tissues have put systematic, high-resolution and comprehensive reference maps of all human cells within reach. We can now realistically envision a human cell atlas to serve as a basis for both understanding human health and diagnosing, monitoring, and treating disease. This is an ambitious but achievable goal, and requires an international community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians. A complete Human Cell Atlas (HCA) would give us a unique ID card for each cell type, a three-dimensional map of how cell types work together to form tissues, knowledge of how all body systems are connected, and insights into how changes in the map underlie health and disease.

Session Objectives:  
• Discuss the need for a human cell atlas in understanding human health and disease.  
• Discuss the utility of single-cell sequencing in molecular diagnostics.  
• Understand the role of single-cell sequencing and HCA play in understanding and treating diseases.

COVID-19 Molecular Testing: Experiences from the Field  
Tuesday, November 17, 4:00 pm – 5:30 pm
COVID-19 Molecular Testing: Experiences from the Field
Teresa A. Karre, MD, Nebraska Methodist Hospital and Children’s Hospital and Medical Center, Omaha, NE, USA
Anthony Tran, DrPH, MPH, D(ABMM), District of Columbia Department of Forensic Sciences, Bethesda, MD, USA
Beth M. Marlowe, PhD, D(ABMM), Quest Diagnostics, San Juan Capistrano, CA, USA
Michael Bachman, MD PhD, University of Michigan/Michigan Medicine, Ann Arbor, MI, USA

Session Description: In a discussion based format, four expert clinical microbiologists from academic, reference, and public health laboratories will discuss challenges and triumphs associated with SARS-CoV-2 molecular testing during the COVID-19 pandemic.

Session Objectives:
• Discuss the evolution of SARS-CoV-2 molecular testing from the beginning of the COVID-19 pandemic to current day.
• Describe challenges of molecular SARS-CoV-2 testing, including but not limited to government regulation and supply shortages.
• Identify ways in which the laboratory medicine has triumphed and grown stronger as a result of the COVID-19 pandemic.

High-throughput functional and genomic approaches for understanding germline and somatic variants
Tuesday, November 17, 4:00 pm – 5:30 pm

Session Type: Live
CE Credit: 1.5
Path: Oncology

Saturation Genome Editing for Variant Effect Prediction
Jay A. Shendure, MD, PhD, University of Washington, Seattle, WA, USA

Validating Oncogenic Somatic Mutations: A Computational and Functional Approach
Collin Tokheim, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Session Description: Variants of uncertain significance are routinely detected during diagnostic testing for constitutional genetic disorders. This session will describe high throughput methods for functional validation that can provide evidence for or against the pathogenicity of these variants.

Session Objectives:
• Describe approaches for high throughput functional and genomic characterization of variants.
• Compare methods for high throughput functional validation.
• Apply high throughput functional validation results to variant classification.
**Laboratory Economics During a Public Health Emergency: Lessons Learned (and still learning) from the COVID-19 Pandemic**

(Sponsored by the AMP Economic Affairs Committee)

Tuesday, November 17, 4:00 pm – 5:15 pm

**Session Type:** Live  
**CE Credit:** 1.5  
**Path:** Advocacy, Lab Management  
**Moderator:** Erika Miller, CRD Associates, Washington, D.C., USA

**Session Description:** The Economic Affairs Committee (EAC) invites you to participate in a dynamic discussion about the lessons we learned and are still learning about reimbursement policies for, needs of, and issues faced by laboratories during the COVID-19 public health emergency. While the Federal government endeavored to create new policies and adapt to the needs for diagnostic tests during the pandemic, some policies have created confusion for patients and laboratories. Looking forward, it is unclear how reimbursement policies will be maintained once the public health emergency is declared over. These uncertainties have resulted in great concerns within the laboratory community about maintaining COVID-19 testing capacity throughout the entire pandemic. Proper and flexible coverage and reimbursement policies need to be in place during a pandemic so that laboratories can continue to support the U.S. population’s public health needs and so that patients are able to easily access these crucial tests. The AMP EAC has worked avidly throughout 2020 to help elicit such an outcome. Please join us for an in-depth discussion about the road-blocks that were encountered throughout coverage, coding, and pricing of COVID-19 diagnostic tests, and explore ideas that could help avoid these problems to quickly get high quality diagnostic tests to patients in future health emergencies.

**Session Objectives:**
- Understand process of coding, coverage and pricing during the pandemic.
- Explain the concerns that resulted from this unusual coding and pricing process.
- Discuss difficulties that your laboratory has had with coverage and reimbursement for COVID-19 diagnostic tests.
- Provide input on policies that AMP EAC is advocating for to develop a coding and reimbursement pathway within CMS during future public health emergencies.

---

**Variant Review and Classification Workshop**

Tuesday, November 17, 4:00 pm – 5:30 pm

**Session Type:** Live  
**CE Credit:** 1.5  
**Path:** Informatics, Oncology  
**Moderator:** Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA

**Variant Review and Classification Workshop**

Mark Routbort, MD, PhD, M. D. Anderson Cancer Center, Houston, TX, USA  
Somak Roy, MD, Cincinnati Children’s Hospital Medical Center, Mason, OH, USA  
Laura Tafe, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Session Description: Genomic variants of different classes have distinct characteristics, error profiles, and classification challenges. Allied to this are challenges related to context-specific interpretation. Variant data visualization and review can be critical in resolving and interpreting complex alterations. In this hands-on workshop, the expert speakers will be doing a live interactive session demonstrating the use of Integrative Genomics Viewer (IGV) for viewing and interpreting different types of variants in DNA sequencing and discuss practical strategies for variant classification and interpretation.

Session Objectives:
• Learn basic features and functionalities in IGV.
• Understand the importance of variant visualization in resolving complex alterations.

Technologist Mixer: Navigating Opportunities for Career Advancement and Certification for Molecular Technologists
Tuesday, November 17, 5:30 pm – 6:15 pm

International Affairs Committee Networking Meet-up
Wednesday, November 18, 10:15 am – 11:00 am

Interactive Expo Hall
Wednesday, November 18, 11:00 am – 11:45 am

Chat with the 2020 Program Chair (Dr. Jane Gibson) & the 2021 Program Chair (Dr. Laura Tafe)
Wednesday, November 18, 11:45 am – 12:00 pm

Coronavirus Pandemic Updates
Wednesday, November 18, 12:00 pm – 1:00 pm

Session Type: Live
CE Credit: 1
Path: Infectious Diseases
Moderators: Esther Babady, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA and Erin McElvania, PhD, NorthShore University HealthSystem, Evanston, IL, USA

Coronavirus Pandemic Updates
Carlos del Rio, MD, Emory School of Medicine, Decatur, GA, USA

Session Description: The COVID-19 pandemic has changed life as we know it worldwide. Molecular diagnostics are the backbone of diagnosis and prevention efforts surrounding this deadly virus. This lecture will give an evolution from where we started to what we know now focusing on the impact of molecular diagnostics.

Session Objectives:
• Provide an a history and update on the COVID-19 pandemic.
• Identify the impact of molecular diagnostics on SARS-CoV-2 diagnosis, tracking, and prevention efforts.
Bridging the Gap: Molecular Tumor Boards, Clinical Trials Matching, and the Pathologist-oncologist Interface

Wednesday, November 18, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Oncology
Moderator: Jonathan A. Nowak, MD, PhD, Brigham and Women’s Hospital, Boston, MA, USA

Precision Oncology Through a Molecular Tumor Board: Hype or Reality?
Marios Giannakis, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Cancer Clinical Decision Making Tools in the Era of Precision Medicine & Big Data
Mia Levy, MD, PhD, Rush University Medical Center, Chicago, IL, USA

Session Description: Next-generation sequencing provides an increasing wealth of information that can be helpful to improve patient care. However, optimal use of this information requires not only a detailed understanding of tumor biology, but also standard of care therapeutic recommendations, clinical trial options and a patients’ individual situation. Molecular tumor boards offer an opportunity to address this challenge by bridging the gap between molecular pathologists and medical oncologists. This session will explore different models for molecular tumor function and will highlight opportunities to improve patient care by bridging the pathology-oncology gap.

Session Objectives:
• Understand the elements and operational considerations of a molecular tumor board.
• Describe the role of the molecular tumor board in guiding precision oncology.
• Understand how shared genomic resources and knowledgebases can contribute to precision oncology.

Distributed Laboratories and Third Party Interpretation Services

Wednesday, November 18, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Lab Management
Moderator: Roger D. Klein, MD, JD, OmniSeq, Beachwood, OH, USA

Distributed Laboratories and Third Party Interpretation Services
Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA
Gail Javitt, Hyman, Phelps & McNamara, Washington, D.C., USA
Matthew Lebo, PhD, Lab for Molecular Medicine, Mass General Brigham Personalized Medicine, Cambridge, MA, USA
Rakesh Nagarajan, MD, PhD, PierianDx, Creve Coeur, MO, USA

Session Description: In the last several years, some laboratories have started providing isolated wetlab or interpretation services. This session will explore the practice and regulation of such distributed laboratory services.
Session Objectives:
• Upon completion, participant will be able to describe the workflow of distributed testing and interpretation services.
• Upon completion, participant will be able to describe the regulatory issues related to distributed testing and interpretation.

Early Detection and Characterization of Cancer Using cfDNA and Distinction from Clonal Hematopoiesis

Wednesday, November 18, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Informatics, Oncology
Moderator: Noah Brown, MD, University of Michigan, Ann Arbor, MI, USA and Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA

Clonal Hematopoiesis Detected from cfDNA Testing
Pedram Razavi, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

cfDNA to Detect and Characterize Cancer at Early Stages
Victor Velculescu, MD, PhD, John Hopkin’s Medicine, Baltimore, MD, USA

Session Description: Cell free DNA has great potential as a biomarker for early detection of cancer as well as monitoring response to therapy in patients in a minimally invasive way. However, there are technical challenges that need to be considered before utilizing this technology in practice. This session aims to discuss novel methodologies in early detection of cancer. This session will also address the frequency of clonal hematopoiesis inadvertently detected during cell-free DNA intended for solid tumor cancer patients, the importance evaluating matched white blood cells and the appropriate next steps when clonal hematopoiesis is detected as an incidental finding.

Session Objectives:
• Describe ways in which cfDNA can be used for early cancer detection and challenges involved.
• Understand the frequency of clonal hematopoiesis inadvertently detected during cell-free DNA testing for solid tumors.
• Understand how clonal hematopoiesis can be distinguished from oncogenic mutations within cfDNA from solid tumor cancer cells.

Point-Counter Point: Clinical Metagenomics Is It Worth the Juice

Wednesday, November 18, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Infectious Diseases
Moderator: Erin H. Graf, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA
Point-counter Point: Clinical Metagenomics Is It Worth the Juice
Steve Miller, MD PhD, University of California San Francisco, San Francisco, CA, USA
Stephanie L. Mitchell, PhD, D(ABMM), University of Pittsburgh, Pittsburgh, PA, USA
William J. Muller, MD, PhD, Lurie Children's Hospital of Chicago; Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Debra Palazzi, MD, MEd, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA

Session Description: In a point/counter point format, the utility of clinical metagenomics to impact patient outcomes will be discussed. Two teams, each with an infectious disease physician and a Micro director from opposite side of this issue.

Session Objectives:
• Discuss the advantages and clinical utility of metagenomics for use in patient care.
• Describe the downsides or harm that metagenomics can cause to patient care.
• Identify clinical situations in which metagenomics is or is not appropriate.

Interactive Expo Hall with Demos and Drawings
Wednesday, November 18, 2:30 pm – 3:30 pm

Chat Room Discussion - Meet a Membership Affairs Committee (MAC) Member
Wednesday, November 18, 2:30 pm – 3:30 pm

Corporate Workshops
Wednesday, November 18, 3:30 pm – 5:30 pm

Business Meeting
Wednesday, November 18, 5:30 pm – 6:15 pm

Social Event – Wine Tasting Event
Wednesday, November 18, 6:15 pm – 7:00 pm

Interactive Expo Hall
Thursday, November 19, 11:00 am – 11:45 am

Chat with the 2020 Program Chair (Dr. Jane Gibson) & the 2021 Program Chair (Dr. Laura Tafe)
Thursday, November 19, 11:45 am – 12:00 pm

Machine Learning in Health Care
Thursday, November 19, 12:00 pm – 1:00 pm

Session Type: Live
CE Credit: 1 | SAM: 1
Path: Informatics, Inherited Conditions
Moderator: Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA and Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA
Machine Learning in Genomic Medicine
Stephen F. Kingsmore, MD DSc FRCPATH, Rady Children’s Institute for Genomic Medicine, San Diego, CA, USA

Session Description: One of the critical bottlenecks in implementing genomics in the critical care setting remains the availability of rapid analytic platforms. In this plenary session, the speaker will describe ultra-rapid whole genome sequencing (urWGS) for diagnosis and management of children in intensive care units. You will learn about the application of machine learning and clinical natural language processing algorithms to perform urWGS as well as the indications, clinical utility of WGS in ICUs, and the impact of urWGS on healthcare utilization in children’s hospital systems.

Session Objectives:
• Understand the indications and clinical utility of urWGS.
• Understand the role of machine learning algorithms in urWGS.

Platform Presentations of Selected Informatics Abstracts
Thursday, November 19, 1:00 pm – 2:00 pm

Session Type: On Demand
CE Credit: 1
Path: Informatics
Moderator: Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA
Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to "chat" with the authors, please do so during the designated poster times in the Poster Hall.

• Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
• Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

I08 - Microhaplotype Locus-based Workflow for Sample Contamination Detection in Multiplexed Next Generation Sequencing (NGS) Assays
Jagadheshwar Balan, MS, Mayo Clinic, Rochester, MN, USA

I14 - ReGe: A Toolkit for Moving Clinical Panels to hg38
Andrew Skol, PhD, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA

I23 - Many NGS-based Assays, One Platform: Ensuring a High-quality Case Review and Sign-out Process with NGS Reporter (NGSR)
Andrea Sboner, PhD, Weill Cornell Medicine, New York, NY, USA

I28 - Building a Comprehensive Teaching Repository of Whole Slide Images
Egiebade E. Iriabho, MSc, The University of Alabama at Birmingham, Birmingham, AL, USA

Session Description: Platform presentations of selected Informatics abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Informatics Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Platform Presentations of Selected Solid Tumors Abstracts
Thursday, November 19, 1:00 pm – 2:00 pm
Session Type: On Demand
CE Credit: 1
Path: Oncology
Moderator: Jonathan A. Nowak, MD, PhD, Brigham and Women’s Hospital, Boston, MA, USA
Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to “chat” with the authors, please do so during the designated poster times in the Poster Hall.

- Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
- Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

ST48 - Tumor Microbiome in Colorectal Carcinoma: Bacterial Enrichment Is Associated with Oncogenic Variants Within Specific Signaling Pathways
Cameron Beech, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ST50 - Comprehensive Genomic Profiling of Different Subsets of Merkel Cell Carcinoma: Insights on Pathogenetic Pathways
Ryan C. DeCoste, MD, QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

ST58 - Genomic Profiling Uncovers Mutation Signatures That Differentiate Pediatric Rhabdomyosarcoma (RMS) Subgroups and Predict Clinical Outcomes
Fumin Lin, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

ST80 - Prospective Study Using Virtual Enrollment to Assess an RNA-FIT Assay for Non-invasive Detection of Colorectal Cancer, Advanced Adenomas, and Other Precancerous Adenomas
Erica K. Barnell, PhD, Geneoscopy Inc., Saint Louis, MO, USA

Session Description: Platform presentations of selected Solid Tumors abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Solid Tumors Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Platform Presentations of Selected Technical Topics Abstracts

Thursday, November 19, 1:00 pm – 2:00 pm

Session Type: On Demand
CE Credit: 1
Path: Molecular Methodologies & Technologies
Moderator: Jennifer Bergendahl, MT(ASCP), Michigan Medicine, Northville, MI, USA
Note: these sessions are On Demand and have been pre-recorded, you can view them in the Auditorium. If you would like to “chat” with the authors, please do so during the designated poster times in the Poster Hall.

- Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
- Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

TT04 - Performance Validation of Magnis BR: A Full-automatic Capture-based Library Preparation Platform for Next-generation Sequencing (NGS)
Xiaotian Wang, PhD, Burning Rock Dx, Shanghai, China

TT06 - Concordance of Variant Detection Between the MoCha ctDNA Assay and Matched Tissue Biopsy in Non-Small Cell Lung Cancer
Chris Karlovich, PhD, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
TT10 - Comparative Study of Three Assays: Target Capture Sequencing, MassARRAY and Real-Time qPCR for Testing Somatic Mutations in Plasma Cell-Free Circulation Tumour DNA of Non-Small Cell Lung Cancer
Lei Zhang, PhD, University of Alberta, Edmonton, Alberta, Canada

TT34 - Optical Mapping Enables High-throughput Analysis of Pathogenic Repeats
Ernest Lam, PhD, Bionano Genomics, San Diego, CA, USA

Session Description: Platform presentations of selected Technical Topics abstracts.

Session Objectives:
• Analyze platform presentations of abstracts highlighted by the Technical Topics Subdivision leadership as particularly significant.
• Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Interactive Expo Hall with Demos and Drawings
Thursday, November 19, 2:00 pm – 3:00 pm

Addressing the Clinical Laboratory Workforce Shortage
Thursday, November 19, 3:00 pm – 4:00 pm

Session Type: Live
CE Credit: 0
Path: Infectious Diseases, Informatics, Inherited Conditions, Lab Management, Molecular Methodologies & Technologies, Oncology
Moderators: Jennifer Bergendahl, MT(ASCP), Michigan Medicine, Northville, MI, USA and Renee Webb, BS, MT (ASCP), Texas Children’s Hospital, Houston, TX, USA

Addressing the Clinical Laboratory Workforce Shortage
Susanne Norris-Zanto, MPH, Laboratory SolutionZ, Helena, MT, USA

Addressing the Clinical Laboratory Workforce Shortage - Automation and Robotics
Jose Manuel Collados, Industrial Engineer, ABB, Houston, TX, USA

Session Description: Effects of the current shortage of qualified clinical laboratory professionals are being felt throughout the laboratory community. This session will describe recent data on the workforce shortage, reasons for the shortage, and the impact on laboratories, patient care, and educational facilities. New solutions for addressing the workforce shortage will also be presented, highlighting new partnerships between healthcare and robotics and the roadmap for robotics implementation in the clinical laboratory.

Session Objectives:
• Understand the drivers behind the current laboratory workforce shortage.
• Gain insight on the impact of staffing shortages on clinical laboratories, patients and academics.
• Learn of newly-developed laboratory-specific robotics that could alleviate the workforce deficit in the clinical laboratory.

Next Generation Guidelines for Clinical Sequencing: Translating Regulations into Practical Implementation Frameworks
Thursday, November 19, 3:00 pm – 4:00 pm
Next Generation Guidelines for Clinical Sequencing: Translating Regulations into Practical Implementation Frameworks
Birgit Funke, PhD, FACMG, Sema4, Newton, MA, USA
Annette Leon, PhD, MS, FACMG, Color, Burlingame, CA, USA

Session Description: Clinical NGS is going mainstream and its applications are increasing. A growing number of guidelines and recommendations have been issued but generally do not provide sufficient concrete instructions on how to translate them into laboratory practice. This course will cover an effort by the Clinical Laboratory Standards Institute (CLSI) to introduce practical guidance for clinical applications of NGS.

Session Objectives:
• Enable laboratory professionals to develop and operate high complexity sequencing tests.

Next-generation Sequencing Assay Development and Validation Q&A
Thursday, November 19, 3:00 pm – 4:00 pm

Session Type: Live
CE Credit: 1
Path: Informatics, Molecular Methodologies & Technologies
Moderators: Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA and Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA

Next-generation Sequencing Assay Development and Validation Q&A
Dara Aisner, MD, PhD, University of Colorado Hospital, Aurora, CO, USA
Ryma Benayed, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Eric Konnick, MD, MS, University of Washington Department of Laboratory Medicine and Pathology, Seattle, WA, USA
Jeremy Segal, MD, PhD, University of Chicago, Chicago, IL, USA

Session Description: Please join us for a live Q&A session and interactive discussion with experts in genomic diagnostics. This will be a highly anticipated follow-up to the Short Course held earlier in the week. Please check on the onDemand recording in the sessions listings for Tuesday, November 17th to watch the session ahead of the Q&A.

Session Objectives:
• Describe best practices for designing panels for DNA and RNA sequencing applications.
• Recognize steps in designing and implementing bioinformatics pipelines from aligning sequencing reads to detecting various genomic alterations.
• List the principles of validation and implementation of NGS based assays.

Tissue Stewardship: Maximizing the Information That Can Be Provided by Small Specimens
Thursday, November 19, 3:00 pm – 4:00 pm
**Session Type:** Live  
**CE Credit:** 1 | **SAM:** 1  
**Path:** Oncology  
**Moderator:** Jonathan A. Nowak, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

**Optimal Assay Design for Small Specimens**  
Christopher Gilbert, DO, MS, Swedish Cancer Institute, Seattle, WA, USA

**Best Practices for Tissue Allocation**  
Sinchita Roy-Chowdhuri, MD, PhD, The University of Texas MD Anderson, Houston, TX, USA

**Session Description:** Across tumor types, the expanding use of molecular profiling and biomarker analysis places increased demands on often limited amounts of tissue. As targeted therapies move into first-line settings, as the use of neoadjuvant therapy increase, and as biopsy size shrinks, optimized and comprehensive testing from small biopsy specimens is increasingly necessary. This session will explore how recently released joint AMP and CAP guidelines regarding optimal tissue allocation and testing strategies that can maximize the amount of information which can be gleaned from small tissue samples.

**Session Objectives:**  
• Describe the role of the pathologist in triaging small specimens to maximize diagnostic utility.  
• Understand how appropriate assay design and selection can reduce tissue requirements for testing.

---

**True or False: Interpretation Challenges of Blood Culture Identification Panels**  
Thursday, November 19, 3:00 pm – 4:00 pm

**Session Type:** Live  
**CE Credit:** 1 | **SAM:** 1  
**Path:** Infectious Diseases  
**Moderator:** Erin McElvania, PhD, NorthShore University HealthSystem, Evanston, IL, USA

**True or False: Interpretation Challenges of Blood Culture Identification Panels**  
Susan Butler-Wu, PhD, LA County and USC Medical Center, Los Angeles, CA, USA

**Pitfalls in Interpretation of Blood Culture Molecular ID Panels**  
Richard E. Davis, PhD, D(ABMM), MLS(ASCP)CM, Providence Sacred Heart Medical Center, Spokane, WA, USA

**Session Description:** In a case format, the speakers will describe the advantages and limitations of molecular panels used for identification of pathogens and resistance markers from positive blood cultures.

**Session Objectives:**  
• Understand the complexities and challenges associated with diagnosis and biomarker testing in small biopsy and cytology samples.  
• Learn judicious ways to triage and optimize the use of small specimens for diagnostic and molecular/biomarker testing.  
• Discuss approaches for optimal tissue collection and processing to maximize chances of ensuring successful molecular testing in non small-cell lung cancer specimens.

---

**Enhanced Molecular Diagnosis Through Structural Variant Detection**  
Thursday, November 19, 4:00 pm – 5:30 pm
Mate Pair Sequencing as a Tool to Increase Diagnostic Yield for Constitutional Genetic Disorders
Nicole Hoppman, PhD, Mayo Clinic, Rochester, MN, USA

Application of New Methods of Structural Variant Detection in the Clinical Laboratory
Madhuri Hegde, PhD, PerkinElmer, Duluth, GA, USA

Simple and Complex Variants Detected by Short and Long Read Sequencing
Stephen Lincoln, Invitae, Potomac, MD, USA

Session Description: Technological advancements have increased the ability to detect structural variants. These new tools are now being applied by laboratories for the diagnosis of constitutional disorders in affected individuals. This session seeks to highlight the potential for new structural variant detection methods to impact clinical diagnosis and provide practical guidance for clinical laboratories interested in adopting these methods.

Session Objectives:
• Recognize the contribution of structural variants to constitutional genetic disorders.
• Evaluate new technologies for the high-resolution detection of structural variants.

Genomics in Children: Coming of Age
Thursday, November 19, 4:00 pm – 5:30 pm

The Current State of the Field in Pediatric Cancer Genomics and Rare Disorders
Sharon E. Plon, Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA

Utility of WGS in Molecular Analysis Pediatric Cancers Discussing the Pro’s and Con’s Within the Question of Clinical Utility
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, Memphis, TN, USA

Session Description: Genomic disorders manifesting during childhood are distinct in terms of clinical spectrum and genetic etiology. The clinical application of genomic technologies and interpretation of genomic results require careful and unique considerations. In this session, the two speakers will describe the current state of the application of clinical genome-scale technologies to childhood Mendelian disorders and pediatric cancers.

Session Objectives:
• Choose correct genome-scale technology and test for the different clinical applications.
• Explain the different types of genomic technologies and the different variants reported with such technologies.
• Define the evidence for the correct classification of germline variants.
Strain Typing in Clinical and Public Health Laboratories: Migration to Whole Genome Sequencing for Epidemiology Purposes

Thursday, November 19, 4:00 pm – 5:30 pm

**Session Type:** On Demand  
**CE Credit:** 1.5  
**Path:** Infectious Diseases, Informatics, Molecular Methodologies & Technologies  
**Moderator:** Erin McElvania, PhD, NorthShore University HealthSystem, Evanston, IL, USA

**Transitioning from Conventional Typing to Whole Genome Sequencing (WGS) for Public Health Epidemiology**  
*William A. Glover, PhD, North Carolina State Laboratory of Public Health, Raleigh, NC, USA*

**Strain Typing in Clinical and Public Health Laboratory: Migration to Whole Genome Sequencing for Epidemiology Purposes**  
*Sanchita Das, MD, D(ABMM), NIH, Bethesda, MD, USA*

**Session Description:** Whole genome sequencing has the greatest discriminatory power for establishing pathogens relatedness. With the decreased cost of WGS, many laboratories (clinical and public health) have abandoned traditional molecular methods in favor of WGS.

**Session Objectives:**  
- Describe basic concepts of WGS and subtyping methods currently being utilized in hospital and public health microbiology laboratories.  
- Identify the advantages and challenges of moving from conventional typing methods to WGS.  
- Discuss the requirements and infrastructure required to switch from conventional typing to WGS.

---

**The Roadmap to Recognition of Molecular Professionals as Qualified Healthcare Professionals** *(Sponsored by the AMP Professional Relations Committee)*

Thursday, November 19, 4:00 pm – 5:30 pm

**Session Type:** Live  
**CE Credit:** 1.5  
**Path:** Advocacy  
**Moderator:** Charles Mathews, Clearview Healthcare Partners, New York, NY, USA

**The Roadmap to Recognition of Molecular Professionals as Qualified Healthcare Professionals**  
*Andrea Ferreira-Gonzalez, PhD, VCU Heath, Richmond, VA, USA*  
*Elaine Lyon, PhD, HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA*  
*Christina Lockwood, PhD, University of Washington, Seattle, WA, USA*  
*John Schmitz, PhD, D(ABHI, ABMLI), F(AAM), UNC School of Medicine, Chapel Hill, NC, USA*

**Session Description:** The Professional Relations Committee (PRC) invites you to participate in a conversation about the past, present and future advocacy efforts focused on the ability of Board-certified doctoral clinical laboratory professionals to bill CMS under the physician fee schedule (PFS) for their role in performing, interpreting, and reporting individual results for molecular diagnostic tests. AMP has long been an advocate for qualified doctoral clinical laboratory professionals to bill on the PFS and in late 2018, AMP reignited our advocacy in this area through the creation of the Professional Reimbursement Workgroup (a joint workgroup of the PRC and the Economic Affairs Committee, EAC). The workgroup is charged with developing and proposing potential coding solutions for the interpretive work involved with molecular tests as well as ensuring that qualified doctoral
clinical laboratory professionals will also be able to bill for this work. This year, the workgroup launched a landscape analysis of the interpretive work that is performed by both molecular pathologists and clinical laboratory professionals. During the session, the workgroup will report on the results of this study and their next advocacy steps. Additionally, the AMP workgroup will be joined by representatives from the American College of Medical Genetics and Genomics (ACMG), who also reignited their advocacy in this area by releasing a statement on “PhDs as Qualified Healthcare Professionals” in late 2019. Please join us for an in-depth discussion about AMP and ACMG’s current advocacy activities in this area and to learn how AMP members can get more involved in furthering this mission.

**Session Objectives:**
- Understand the CMS billing for professional and interpretive work and explain previous efforts by AMP and others on this topic.
- Gain a clear perspective of AMP’s landscape analysis and understand the gaps between the interpretive work involved with molecular pathology testing and the current reimbursement structure.
- Comprehend the history on this issue and concerns for various professional organizations.
- Learn key ways one can get more involved in this issue.

**What Do All These Mutations Mean?**
Thursday, November 19, 4:00 pm – 5:30 pm

**Session Type:** Live

**CE Credit:** 1.5 | **SAM:** 1.5

**Path:** Oncology

**Moderator:** Mark D. Ewalt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**How Do I Manage a Patient with CH?**
*Kelly Bolton, MD PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA*

**How Can I Use Mutation Data to Diagnose MDS in a Patient with Cytopenia and No Morphologic Dysplasia?**
*Amy E. Dezern, MD, MHS, The Johns Hopkins University School of Medicine, Baltimore, MD, USA*

**Session Description:** Over the last several years, we have come to recognize that healthy individuals often harbor somatic alterations which are detectable in the peripheral blood but are not specifically diagnostic for a hematologic neoplasm, which has been named Clonal Hematopoiesis (CH). In addition, some patients show evidence of clonal hematopoiesis and a cytopenia but no overt evidence of morphologic dysplasia. This session aims to review our understanding of the impact of CH on health and how the presence of multiple clonal mutations may impact diagnosis of a hematologic neoplasm.

**Session Objectives:**
- Understand the effects of CH on health and clinical management strategies.
- Review, in the context of unexplained cytopenia, the diagnostic value of a somatic mutation analysis.

**Innovation Spotlights**
Thursday, November 19, 5:30 pm – 6:30 pm

**Social Event – AMP Talent Show**
Thursday, November 19, 6:00 pm – 7:00 pm
Interactive Expo Hall
Friday, November 20, 11:00 am – 11:45 am

Chat with the 2020 Program Chair (Dr. Jane Gibson) & the 2021 Program Chair (Dr. Laura Tafe)
Friday, November 20, 11:45 am – 12:00 pm

DepMap: The Cancer Dependency Map Project
Friday, November 20, 12:00 pm – 1:00 pm

**Session Type:** Live  
**CE Credit:** 1  
**Path:** Oncology  
**Moderators:** Raj Emmadi, MD, University of Illinois, Chicago, IL, USA and Jonathan A. Nowak, MD, PhD, Brigham and Women’s Hospital, Boston, MA, USA

**Depmap: The Cancer Dependency Map Project**  
William C. Hahn, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

**Session Description:** Applying precision cancer medicine requires an understanding of somatic alterations and their consequences in tumors. This presentation will describe our efforts to comprehensively map genes required for the fitness of human cancers using genome scale genetic approaches.

**Session Objectives:**  
- Understand the concept of a cancer dependency.  
- Understand genome-scale approaches to study gene function.  
- Define different types of cancer targets to enable cancer precision medicine.

Emerging Testing Paradigms and Insights  
Friday, November 20, 1:00 pm – 2:30 pm

**Session Type:** Live  
**CE Credit:** 1.5 | **SAM:** 1.5  
**Path:** Inherited Conditions  
**Moderator:** Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA

**Experience from Proactive Whole Genome Sequencing in 400 Newborn Children**  
Steven B. Bleyl, PHD, MD, Genome Medical Services, S. San Francisco, CA, USA

**Genetic Testing as an Employee Benefit**  
Scott Topper, PhD, Color, Burlingame, CA, USA

**Translational Research Approaches to Large-scale Population Genomics**  
James Lu, MD, PhD, Helix, San Mateo, CA, USA

**Session Description:** Genetic testing models have proliferated beyond the traditional clinical setting. This session will explore some of the non-traditional models and insights that have arisen from them.
Session Objectives:
• Upon completion, participant will be able to describe some of the services that do not fit into a traditional CLIA testing framework.
• Upon completion, participant will be able to describe the advantages and disadvantages of some emerging testing services.

Genomically-informed Lymphoma Classification

Friday, November 20, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Oncology
Moderator: Mark D. Ewalt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Molecular Updates in Classification of B-cell Lymphomas
Sandeep Dave, MD, Duke University, Durham, NC, USA

Molecular Updates in Classification of T-cell Lymphomas
Javeed Iqbal, MS PhD, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA

Session Description: The past several years have seen an explosion in genomic information in lymphoid neoplasms. This information has helped to refine our classification systems of B- and T-cell lymphoproliferative disorders. This session aims to review major updates to the molecular classification of lymphoid neoplasms and suggestions for how to incorporate this into molecular hematopathology practice.

Session Objectives:
• Describe how gene expression profiling and molecular classification can delineate novel subtypes of T-cell lymphoma.
• Discuss novel classifications of B-cell lymphoma based on genetic information.

Next Generation Data: Integration and Dissemination of Molecular Pathology Data

Friday, November 20, 1:00 pm – 2:30 pm

Session Type: On Demand
CE Credit: 1.5
Path: Informatics
Moderator: Angshumoy Roy, MD, PhD, Baylor College of Medicine, Houston, TX, USA

Modern Application Deployment Strategies for NGS Testing and Integration with Molecular Pathology Data
Cihan Kaya, PhD, Molecular and Genomic Pathology Lab, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Next Generation Data: Integration and Dissemination of Molecular Pathology Data
Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA
Session Description: Molecular pathology generates multitude of data points for each specimen received. With increasing adoption of NGS assays, managing and sharing data has become harder but more important than ever. This session will discuss best practises around managing, reviewing, integrating and disseminating molecular pathology data. Participants will discuss their experiences and tools developed/used for this process.

Session Objectives:
• Best practices for developing software tools for molecular pathology applications.
• Integrating data from disparate data sources; not only from molecular tests but from across all pathology.

Tumor Evolution and Therapeutic Resistance
Friday, November 20, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5
Path: Oncology
Moderator: Raj Emmadi, MD, University of Illinois, Chicago, IL, USA

In-silico Modeling of Tumor Evolution
Noam Auslander, PhD, National institute of Biotechnology Information, NIH, Bethesda, MD, USA

Molecular Archeology of Cancer
Peter Van Loo, PhD, The Francis Crick Institute., London, England, United Kingdom

Session Description: The cancer genome contains an evolutionary record of the tumor's past. Mining this record can show us the timelines of tumor evolution. Studying this mutational landscape through neural nets and other computational modeling allows for a more comprehensive view of mutational process, burdens and hierarchical sequence, allowing for clearer definitions of tumor progressions and therapeutic implications. It also opens up opportunities for future early diagnostic approaches.

Session Objectives:
• Understand how methods of massively parallel sequencing and computational modeling can be used to elucidate and model the temporal sequence of tumor progression and evolution.
• Investigate tumor progression and construct clinically relevant mutational profiles.
• Understand how characterization of tumor evolution can impact clinical care and identify opportunities for future early diagnosis of cancer.

Whole Genome Sequencing for Antimicrobial Resistance Testing
Friday, November 20, 1:00 pm – 2:30 pm

Session Type: Live
CE Credit: 1.5 | SAM: 1.5
Path: Infectious Diseases, Informatics, Molecular Methodologies & Technologies
Moderator: Esther Babady, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Detection of Resistance-associated Mutations in Cytomegalovirus Through the Use of Next-generation Sequencing
Matthew Binnicker, PhD, Mayo Clinic, Rochester, MN, USA
Clinical Whole-genome Sequencing and Drug Resistance Reporting for mycobacterium tuberculosis in New York: A 5 Year Summary
Kimberlee Musser, PhD, Wadsworth Center, New York Department of Health, Wadsworth Center, Loudonville, NY, USA

Session Description: Describe and discuss the use of WGS for the routine detection and monitoring of antimicrobial resistance of pathogens of clinical importance.

Session Objectives:
• Understand the basic design of a Next generation sequencing (NGS) whole-genome sequencing (WGS) approach to detect mutations of clinical significance.
• Discuss the application of next-generation sequencing for the detection and identification of resistance-associated mutations for Mycobacterium tuberculosis and cytomegalovirus.
• Be familiar with interpretation and reporting of NGS WGS testing.

Interactive Expo Hall with Demos and Drawings
Friday, November 20, 2:30 pm – 3:30 pm

Gene Therapy for Retinal Disorders
Friday, November 20, 3:30 pm – 4:30 pm

Session Type: Live
CE Credit: 1
Path: Inherited Conditions
Moderator: Hyunseok Kang, MD, MS, Natera, Inc., Los Altos Hills, CA, USA

Gene Therapy for Retinal Disorders
Elias Traboulsi, MD, MEd, Cleveland Clinic, Cleveland, OH, USA

Session Description: In the last several years, there have been significant advances in the area of targeted therapies for constitutional genetic disorders. In 2017, the FDA approved its first gene therapy, Luxturna, for the treatment of RPE65-associated retinal dystrophy. As a result of this breakthrough, gene therapy trials are underway for a variety of other retinal disorders. Retinal disorders exemplify the emerging paradigm that links molecular diagnostic testing for constitutional genetic disorders to targeted therapies.

Session Objectives:
• Upon completion, participant will be able to describe novel targeted therapies for various genetic disorders.
• Upon completion, participant will be able to describe the mechanisms of targeted therapies and patient prognosis.

Closing Remarks
Friday, November 20, 4:30 pm – 4:45 pm
General Poster Information

- All poster will be on display in the “Poster Hall” of the AMP Virtual Platform. There, you’ll be able...
  - View the ePosters (PDF File)
  - View Video Presentations (if submitted by author)
  - Chat with and ask the authors questions during the designated Poster Presentations times (see below). You will do this by using the “Chat” Function within each poster listing.

- Please note that poster-viewing is not eligible for Continuing Education credit.

- Abstracts can be viewed online here: [https://www.jmdjournal.org/issue/S1525-1578(19)X0018-5](https://www.jmdjournal.org/issue/S1525-1578(19)X0018-5)

- Posters are arranged by category and listed in sequential order by number in the following format:

  Poster Number  Abstract Title  
  First Author’s Name

  Key to poster categories:
  G = Genetics
  I = Informatics
  HP = Hematopathology  OTH = Other
  ID = Infectious Diseases  ST = Solid Tumors
  TT = Technical Topics

Award Applicant Information

- All Award Applicant posters display in Poster Number order in the areas of their subject category. They are identified as Technologist or YIA Award Applicant within the Poster Title Listing.

- All Award Applicants must attend their posters on Tuesday, November 17, 1:00pm – 2:00pm for interviews with members of the poster reviewing committees via the chat function within the virtual platform.

Author/Presenter Information

- All First/Presenting Authors, including Award Applicants, must attend their posters either Tuesday afternoon (even-numbered posters) or Thursday morning (odd-numbered posters):
  - Even-numbered posters must be attended on Tuesday, November 17, 1:00pm – 2:00pm
  - Odd-numbered posters will be attended on Thursday, November 19, 1:00pm – 2:00pm

- Authors who have more than one even- or odd-numbered poster may either ask another author to attend their additional poster or attend it themselves during the other session. In the latter case, the author should type a message in the chat function alerting attendees that they will attend the poster in the alternate session.
Poster Listing

Even numbered ePosters will be attended by their authors on Tuesday, November 17, 1:00pm – 2:00pm Eastern

Odd numbered ePosters will be attended by their authors on Thursday, November 19, 1:00pm – 2:00pm Eastern.

GENETICS

G01. Development and Validation of a High-Throughput Next-Generation Sequencing Assay from Buccal Cell DNA as a Cost-Effective Screening Method for Celiac Genetic Risk
S. Gunn

G02. Copy Number Variant Analysis Improves the Diagnostic Yield in a Cohort of Pediatric Patients with Previously Negative Constitutional Exome Sequencing Results
E. Hahn

G03. A Retrospective Study of Products of Conception with More Than 44,000 Specimens in 27 Years at a National Cytogenetic Reference Laboratory
H. Meng

G04. WITHDRAWN

G05. Reevaluation of Genomic Test Results for Germline Disorders: A Framework of Critical Considerations on Behalf of CLSI Document Development Committee (DDC) on Nucleic Acid Sequencing (MM09)
J. Ji

G06. Single Gene Transcript Analysis and 3D Modeling: An Integrated Approach to Variant Assessment
F. Vetrini

G07. Detection of Allelic Dropout in a Mass Array HFE Genotyping Assay
A. Campbell

G08. Result Interpretation for Clinical Exome and Genome Sequencing: On Behalf of CLSI Document Development Committee (DDC) on Nucleic Acid Sequencing (MM09)
J. Buchan

G09. Incidental Diagnosis of NR5A1-Related 46,XY Disorder of Testicular Development in Neonate with Mosaic Partial Trisomy 2q
S. Vallee

G10. Optimization and Validation of a Sanger Sequencing Clinical Assay for Germline BRCA1/2 Gene Mutation Detection at King Hussein Cancer Center
W. Naser

G11. Mosaicism in Cancer Susceptibility Genes in Unselected Cancer Patients
D. Mandelker
D. Toledo

G13. Comparison of Universal versus Traditional Genetic Testing Models for Cancer Patients
O. Ceyhan-Birsoy

T. Huard

T. Prior

G16. A Rare Single Nucleotide Variant Causing a False-Negative HTT CAG Repeat Expansion Result in the Evaluation of a Patient for Huntington Disease
F. El-Sharkawy

G17. Amplification-Free Targeted Enrichment Powered by CRISPR-Cas9 and Long-Read Single Molecule Real-Time Sequencing Can Efficiently and Accurately Sequence Challenging Repeat Expansion Disorders
J. Ekholm

G18. A Single-Assay Diagnostic Workflow for Genotyping and Phasing SNPs with Repeat Expansions for Allele-Selective Therapy in Huntington Disease
S. Statt

M. Avenarius

G20. Test Validation and Characterization of Reference Materials for ADH5 Genotyping
A. Otsubo

G21. CYP2D6 Guided Methadone Dosing in a Multi-Ethnic Population: A Pharmacogenomic Screen to Decrease Withdrawal Morbidity
C. Lum

G22. Developing DPYD Genotyping Method for Personalized 5-fluorouracil Therapy
B. Wong

G23. High-Throughput Fetal-Fraction Amplification Increases Analytical Performance of Noninvasive Prenatal Screening
D. Muzzey

G24. A Software Tool That Prevents Incorrect Estimations of Gestational Age and Maternal Age at Estimated Date of Delivery Reported by the College of American Pathologists NIPT Participant Summary
Y. Wang

G25. Genetic Insights and Incidental Findings from Maternal Cell Contamination Testing
N. Kopp

G26. The Relationship between Variant Type and Phenotype among Diseases Screened by the Foresight Expanded Carrier Screen
K. Karimi
G27. **Two-Site Evaluation of a Rapid and Simple CFTR PCR/CE Assay and Software Targeting Mutations across Diverse Ethnic Groups**  
*S. Filipovic-Sadic*

G28. **SMN1 and SMN2 Copy Number Distribution in 733 Clinical Cases of Carrier Screening for Spinal Muscular Atrophy**  
*D. Toledo*

G29. **Proof-of-Concept for Single-Platform Trio Carrier Screening of FMR1, SMN1/2, and CFTR Variants Using PCR and Capillary Electrophoresis with Consolidated Workflows**  
*W. Laosinchai-Wolf*

G30. **The Single-Tube SLIMamp NGS Assay for Detection of Mutations Associated with Thalassemia is both Rapid and Robust**  
*X. Wu*

G31. **Exploring Mosaic Mutations in Megalencephaly and Other Growth Disorders by Next-Generation Sequencing**  
*N. Madkhali*

---

**HEMATOPATHOLOGY**

H01. **Personalized Medicine in Practice: Comprehensive Genomic Profiling of a Lung Adenocarcinoma Leads to Reclassification of a Concurrent Lymphoma**  
*P. Terraf*

H02. **WITHDRAWN**

H03. **Limitation in Confirming Low Allele Frequency Calls from Sensitive Cancer Assays: MSK Experience with the LiquidPlex cfDNA Panel on Hematologic Samples**  
*J. Jeon*

H04. **Somatic Mutation Testing for Pediatric Patients with Known or Suspected Inherited Bone Marrow Failure Syndromes**  
*K. Fisher*

H05. **A Highly Reproducible Single-Day FISH Assay for Detection of t(11;14) in Multiple Myeloma Patient Samples**  
*A. Prokhorova*

H06. **Comparison of Capture-Based Next-Generation Sequencing Designs in a Clinical Myeloid Neoplasm Panel**  
*M. Dina*

H07. **Clinical Utility of a Custom-Designed Next-Generation Sequencing (NGS) Panel for Detection of Gene Fusions, Deletions, and Hotspot Mutations in Myeloid and Lymphoid Neoplasms**  
*R. Starks*

H08. **Genomic Landscape of Primary Breast Lymphoma Diffuse Large B-Cell Lymphoma (PB-DLBCL)**  
*L. Liu*

H09. **Evaluation of the Ion Torrent Oncomine Myeloid Sequencing Panel**  
*B. Houde*
H10. Proteomics-Based Biomarkers in Squamous Cell Carcinoma: A Pilot Study Correlating Proteomic Profiles and Tumor Differentiation
Y. Chen Wongworawat

H11. Detection of Low-Frequency Variants for Minimal Residual Disease (MRD) Monitoring of Acute Myeloid Leukemia
N. Valencia

H12. A Next-Generation DNA Sequencing Assay for Detection of SNVs, Insertions, Deletions, and Copy Number Variants in 25 Lymphoma Genes in Samples
S. Roman

H13. High Throughput TRG Sequencing in a Clinical Laboratory: Analysis of Equivocal Results
V. Smith

H14. CloneRetriever: An Automated Algorithm to Identify Clonal Immunoglobulin Gene Rearrangements by Next-Generation Sequencing
E. Halper-Stromberg

H15. IGH V-Gene Somatic Hypermutation Assessment by Hybrid-Capture
E. Mahe

H16. Comparison of Next-Generation Sequencing-Based TRG and TRB Assays for the Diagnostic Evaluation of T Cell Lymphoid Malignancies
C. Ho

H17. Characterization of the Immunoglobulin Heavy- and Light-Chain Repertoires in a Single Reaction
G. Lowman

H18. Assessment of a High-Throughput Sequencing Assay for Measurable Residual Disease (MRD) Monitoring in Patients with T-Cell Malignancies
J. Tung

H19. Improved Clonality and Somatic Hypermutation Analysis of CLL with a Highly Multiplex IGHV Assay
M. Toro

H20. The Development of an NGS Assay of Immunoglobulin Heavy Variable Gene Somatic Hypermutation in CLL
G. Shi

H21. Validation of MYD88 L265P ddPCR Assay and Application in Assessment of Primary CNS Lymphoproliferative Disorders
M. Cantu

R. Garcia

H23. Precise Detection of PDL1/PDL2 Copy Number Alterations in Classic Hodgkin Lymphoma Using Combined CD30 Immunophenotyping and FISH Analysis
Y. Zhang
J. Schubert

H25. Novel Fusion of PVT1-RCOR1 in B-Cell Prolymphocytic Leukemia (BCPCLL) Producing False FISH Fusion of MYC-IGH with an Atypical Pattern
P. Koduru

H26. Identification of Clinical Molecular Targets for Childhood Burkitt Lymphoma
N. Zeng

H27. Characterization of TP53 Mutations in Myeloid Neoplasms for Targeted Therapy
A. Mindiola Romero

H28. Chromosome Arm Gain or Loss by Next Generation Sequencing
M. Dabrowski

H29. Clinical Significance of CEBPA Double Mutants: Challenges in Variant Classification and Subtyping of Acute Myeloid Leukemia
J. Yoon

H30. Cytogenetic and Molecular Landscape in Hispanic Acute Myeloid Leukemia Patients from Puerto Rico
P. Deb

H31. Evaluation and Follow-up of JAK2 V617F Positive Patients with Low Allele Burden: A Single-Center Experience
K. Reddy

H32. Number of Variants and Pathogenic Variants in ASXL1, STAG2, and RUNX1 Correlate with High Ogata Score by Flow Cytometry in Myelodysplastic Syndromes: A National Reference Laboratory Experience
M. Williams

H33. Clinical Implementation of a Custom Myeloid NGS Assay and Overview of NPM1 and IDH1/IDH2 Mutation Status in a Clinical Cohort
M. Kluk

H34. Development of FIP1L1-PDGFRα Real-time RT-PCR Assay
M. Mai

H35. FLT3-ITD Mutant Allelic Ratio: Impact of Using Non-standardized Published Calculations and Potential Correction Based on Marrow Blast Percentage
J. Reinartz

R. Yang

H37. Curation of FLT3 Variants in Acute Myeloid Leukemia by Clinical Genome Resource Somatic Hematologic Cancer Taskforce (ClinGen HCT)
X. Xu

H38. Persistent IDH Mutations in AML Patients in Remission on IDH Inhibitors
J. Xu
H39. Diagnostic Value of Molecular Markers in the Work-up of Myelodysplastic Syndromes  
R. He

H40. Clinical Validation of Mutant IDH1 and IDH2 Detection by Multiplex Digital Droplet PCR  
J. Racchumi

H41. Comparison of Targeted Myeloproliferative Subpanel versus Comprehensive Myeloid Panel in the Evaluation of Suspected BCR-ABL1-Negative Myeloproliferative Neoplasms  
D. Morlote

H42. Haplotype Phase of CEBPA Mutations in Acute Myeloid Leukemia  
S. Harley

H43. Identifying Non-canonical Mutations in Myeloproliferative Neoplasms: Our Experience with JAK2 Sequencing  
L. Baugh

H44. Comparison of Whole Genome Sequencing (WGS) with Conventional Cytogenetics in Profiling Genome-Wide Large-Scale Copy Number and Structural Variations in Pediatric and Adolescent AML  
L. Wang

H45. Workflow Comparison between Two NCCN Guideline Recommended Myeloproliferative Neoplasms Screening Workup: A Single Institution’s Experience  
N. Tabish

INFECTION DISEASES

ID01. Multisite Evaluation of the ARIES MRSA Assay for the Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) from Nasal Swabs  
B. Buchan

ID02. Comparison of a Cartridge-Based Host Gene Expression Test to a Manual Method for Use in the Diagnosis of Sepsis  
S. Cermelli

ID03. Comparison of Two Multiplex Real-Time PCR Assays for Detection of Tick-Borne Pathogens  
T. Uphoff

ID04. Development and Performance of a Multiplex Polymerase Chain Reaction (PCR)-Based Assay for Detection of Bacteria in Sterile Body Fluids  
C. Johnson

ID05. Automated Multiplex Real-Time PCR Detection of Anaplasma phagocytophilum and Ehrlichia chaffeensis Using the Panther Fusion Open Access System  
K. Stellrecht

ID06. Automated Real-Time PCR Detection of Babesia microti Using the Panther Fusion Open Access System  
K. Stellrecht

ID07. Evaluation of an Automated rRNA Quantitation System for Rapid AST in Clinical Lab Diagnostics  
D. Liu
ID08. Prospective Evaluation of a Multiplex HDPCR Tick-Borne Pathogen Panel
T. Uphoff

ID09. Development of a 29-mRNA Loop Mediated Isothermal Amplification Assay for the Rapid Diagnosis of Acute Infection and Sepsis
M. Remmel

ID10. In silico Performance of a Rapid Sepsis Test in Patients with Candidemia
D. Sampson

ID11. Development of ViroKey SARS-CoV-2 RT-PCR Test v2.0 for the Sensitive and Accurate Automated Detection of the SARS-CoV-2 Virus
I. Ng

ID12. Comparison of Four Commercial Molecular Diagnostic Kits for Detection of SARS-CoV-2: A Pilot Study
P. Chheda

ID13. Evaluation of Ion AmpliSeq SARS-CoV-2 NGS Research Panel
W. Liu

C. Knox

ID15. SARS-CoV-2 Cycle Number as a Metric for Population Trends in New Hampshire
E. Bradley

ID16. Verification of the Centers for Disease Control and Prevention Real-Time SARS-CoV-2 Assay for Emergency Use Authorization
K. Lancor

ID17. Analytical Validation of a SARS-CoV-2 Whole Genome Sequencing Method by Amplicon-Based NGS
S. Rosenthal

C. Wang

ID19. Comparison of Test Performance of Two Rapid SARS-CoV-2 Viral Assays
R. Abdulbaki

S. Glogowski

ID21. Detecting Signatures of SARS-CoV-2 Using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
R. Barney

ID22. A Practical Comparison of Seven Molecular SARS-CoV-2 Methods
C. Gentile

S. Kim
ID24. The Combination Assay for SARS-CoV-2 and Other Respiratory Viruses in Symptomatic Patients and the Statistical Outcome Visualizing Metrics and Trends
S. Lee

ID25. Temporal Spatial Heterogeneity of Immune Response to SARS-CoV-2 Lung Infection
N. Desai

A. Rahman

ID27. Evaluating the Clinical Utility of Next-Generation Sequencing of Nasopharyngeal Specimens for SARS-CoV-2 in the COVID-19 Pandemic
P. Velu

ID28. Validation of Saliva Testing for SARS-CoV-2 on Abbott m2000
S. Amin

ID29. Validation of an Emergency Use Authorization RT-PCR Test for Detecting SARS-CoV-2 in Upper and Lower Respiratory Tract Specimens
L. Cong

M. Steffen

M. Amadei

ID32. Development of a Multiplex Respiratory Panel and a Singleplex SARS-CoV-2 External Control for Use in a Rapid Nucleic Acid Amplification Detection System
J. Salem

ID33. Comparison of Two High-Throughput qPCR Assays for SARS-CoV-2
S. Turner

ID34. Development of a Multiplexed Synthetic Control for Rapid Detection of SARS-CoV-2 and Other Respiratory Pathogens Using a Nucleic Acid Syndromic Testing Panel
T. Schleicher

ID35. Comparison of Nasopharyngeal Swabs and Saliva Samples for the Detection of SARS-CoV-2 RNA
T. McMillen

ID36. Strategy for Analysis of Human ACE2 Putative Variants Linked to Protein Structure and Stability: Implications for ACE2 Receptor Binding to SARS-CoV-2
E. Hughes

ID37. Comparison of Oral Rinses and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 RNA
T. McMillen

ID38. Lung Injury Due to COVID-19 Relative to Influenza and Non-viral ARDS and Normal Controls
A. Borczuk
ID39. Evaluation of Sample Pooling for the Detection of SARS-CoV-2 RNA Using the Cobas SARS-CoV-2 Test
   T. McMillen

ID40. RT-PCR Detection of SARS-CoV-2 Infection in Formalin-Fixed, Paraffin-Embedded Tissue Sections in Autopsy Cases
   D. Berman

ID41. The Evaluation of Oropharyngeal Swabs and Saliva Samples for the Detection of SARS-CoV-2 RNA
   T. McMillen

ID42. Evaluation of a Sample-to-Answer Cartridge-Based SARS-CoV-2 Assay
   J. Lefferts

ID43. Viral Sequencing Suggesting Transmission of SARS-CoV-2 from a Patient with False-Negative Molecular Results to Health Care Providers
   D. Green

ID44. Digital Droplet PCR to Detect Low-Titer SARS-CoV-2 in Nasopharyngeal, Nasal, and Salivary Specimens
   J. Xu

ID45. Leveraging Clinical Metagenomic Testing against SARS-CoV-2
   B. Briggs

ID46. A Systematic Review of the Genomic Diversity of SARS-CoV-2 Virus Detected in Dartmouth-Hitchcock Hospital
   D. Green

ID47. Evaluation of Saliva as an Alternative Sample Type for SARS-CoV-2 Detection Using the Hologic Panther Aptima EUA Assay
   W. Rehrauer

ID48. Automated, High-Throughput Testing Using the RealTime SARS-CoV-2 Assay
   M. Johnston

ID49. The Utility of Repeat Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 by Reverse Transcriptase-Polymerase Chain Reaction in Improving Diagnostic Accuracy
   S. Fathima

ID50. Clinical Performance of GenMark ePlex SARS-CoV-2 Test Compared to a Laboratory Developed Procedure
   J. Laudadio

ID51. Evaluation of the SARS-CoV-2 Chromacode EUA Assay
   L. Thompson

ID52. Design and Optimization of Novel ITS2-28s rRNA Gene Primers for Fungal Species Detection from Formalin-Fixed, Paraffin-Embedded Tissues with a Targeted Next-Generation Sequencing Assay
   G. Wang

ID53. Non-invasive Microbial Cell-Free DNA Sequencing Detects Invasive Mold Infections in Immunocompromised Patients with Pneumonia
   T. Blauwkamp
ID54. A Comparative Study of qPCR to a NGS Metagenomics Assay to Detect and Quantify DNA Viruses in Pediatric Bone Marrow Transplant Patients
L. Cooper

ID55. Investigating Targeted Next-Generation Sequencing of 16S RNA as a Tool for Detecting Shiga Toxin-Producing E. coli and Salmonella in Ground Beef
J. Au-Young

ID56. Subtyping of Human Papillomavirus (HPV) Using Next-Generation Sequencing (NGS) Data in Cervical Cancer: A Feasibility Study with Comparison to Conventional Clinical Assays
J. Chen

ID57. Analytical Performance Characteristics of Galileo ONE: An End-to-End Metagenomics Assay for the Unbiased Sequencing and Bioinformatics Analysis of Microbial DNA and RNA Directly from EDTA Plasma
M. Carpenter

ID58. Application of Whole-Genome Sequencing for Bacterial Strain Typing in Investigating Hospital Infections
K. Park

ID59. Validation of ddPCR-Quantified Standards for Use in Viral Load Measurements by NGS
D. Hoerres

ID60. Performance Evaluation of Abbott Alinity m System to Detect HBV, HCV, and HIV-1 Infections: Comparison with Hologic Panther Aptima System
J. Han

H. Wang

ID62. WITHDRAWN

ID63. Evaluation of a Novel VZV Molecular Assay for Detection of VZV from CSF and Swabs
A. Cruz

ID64. A Multi-Lab Collaboration for Quantitative BK Virus Test Development on the Fully Automated Cobas 6800/8800 OMNI Utility Channel
K. Lebel

ID65. Utilization of Digital PCR Assay for the Detection of HPV-16 in Cell-Free DNA in Patients with Head and Neck Cancer at an Oncology Center
T. McMillen

ID66. Detection of Adenovirus Serotype 7 in a Cancer Patient Population
R. Sumner

ID67. Retrospective Review of Seasonality of Human Parainfluenza Virus Subtypes at an Oncology Center
T. McMillen

ID68. Validation of the RealStar Adenovirus Reagents on Plasma and Stool Samples and Comparison to a Laboratory-Developed Test Using the MultiCode Adenovirus Reagents
C. Lee
INFORMATICS

I01. Assessment of RAS Dependency for \textit{BRAF} Mutations Using Real-World Evidence Databases
G. Zheng

I02. CarrierSeq, an Expanded Carrier Screening Product Using Next-Generation Sequencing Technology
T. Fahland

I03. Evaluation of Roche NAVIFY Mutation Profiler for NGS Variant Annotation and Reporting
P. Ward

I04. Optimizing the Detection of Insertions and Deletions Using Next-Generation Sequencing in the Clinical Laboratory
K. Craven

I05. Optimizing Reference Mixture Samples for Bioinformatics Pipeline Assessment on Variant Calling Detection for Cancer Diagnostics and Treatment
C. Laing

I06. Use and Feasibility of Multi-Algorithimc Consensus-Based Bioinformatics Pipelines in the Detection of Fusions in FFPE Treated Samples
V. Williamson

I07. Highly Scalable and Automated Approach to Gut Microbiome Profiling and Quantification Using a New Ion Torrent Next-Generation Sequencing Assay
S. Sarda

I08. Microhaplotype Locus-Based Workflow for Sample Contamination Detection in Multiplexed Next-Generation Sequencing (NGS) Assays
J. Balan

I09. Prediction of DDR and Other Mutation Signatures Using Panel-Based Sequencing
A. Chellappan

I10. Accurate Detection and Quantification of \textit{FLT3} Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data
J. Tung

I11. Identification of Large Deletions Affecting \textit{CTNNB1} Exon 3 in Solid Tumors
Z. Zhang

I12. Development of a Clinical Bioinformatics Pipeline for the Comprehensive Genomic Profiling of Patient-Derived Xenograft Tumors
S. Turner

I13. Comprehensive Single-Nucleotide, Indel, Structural, and Copy-Number Variant Detection in Human Genomes with PacBio HiFi Reads
W. Rowell

I14. Look before You Leap: A Toolkit for Moving Clinical Panels to GRCh38
A. Skol
115. A Novel Machine Learning Approach to Characterize Cancer Signatures for Improved Clinical Reporting
   S. Shams

116. Pindel as a Back-up INDEL Caller to a GATK4 Mutect2-Based in-House Developed Somatic Secondary Analysis Bioinformatics Pipeline for a Custom Clinical Cancer NGS Panel
   S. Harada

117. Classification Methods for Germline and Somatic Single Nucleotide Variant (SNV) in Circulating Tumor DNA (ctDNA) of Small Cell (SCLC) and Non-small Cell Lung Cancer (NSCLC)
   C. Wöstmann

118. Evaluating Machine Learning Methods for Accurate Variant Calling Detection on Acute Myeloid Mutation Analysis
   C. Laing

   C. Laing

120. Clinical Cancer Genomics: Artificial Intelligence Assisted Data Re-analysis to Improve Detection of Potentially Actionable Mutations
   C. Fischer

121. Capturing and Visualizing Cancer Genomic Data with Category Variants in the JAX Clinical Knowledgebase (JAX-CKB)
   T. Yin

122. MPath STAR-QC: Automated Quality Control Application for Contamination and Sample Swap Detection Using Short Tandem Repeat Testing
   S. Lachhander

123. Many NGS-Based Assays, One Platform: Ensuring a High-Quality Case Review and Sign-out Process with NGS Reporter (NGSR)
   A. Sboner

124. Database for Managing Results of High-Throughput Sequencing Clonality Assays in Clinical Laboratories
   C. Ho

125. MPath Lab QC: A Centralized Assay Agnostic Approach to Store, Review, and Finalize Laboratory QC for NGS-Based Genomic Clinical Tests
   A. Agarunov

126. MPath Results PCR: An Integrated Approach to Programmatically Load, Curate and Report Non-NGS Germline Results
   R. Murray

127. mrLab: Leveraging Mixed Reality in a Precision Medicine Laboratory to Increase Safety and Productivity of Healthcare Workers during the COVID-19 Pandemic
   A. Sigaras

128. Building a Comprehensive Teaching Repository of Whole Slide Images
   E. Iriabho
OTHER (e.g., Education)

OTH01. Effect of Implementation of a Medium-Sized NGS Panel and Organ-Specific Subpanels on Send-out Testing: Experiences of a Small, Hospital-Based Molecular Diagnostics Lab
R. Kumar

OTH02. Establishment of a Multidisciplinary Precision Medicine Lymphoma Tumor Board Incorporating Results of Massively Parallel Sequencing
N. Gupta

OTH03. Educating in a Pandemic: Rapid Changes to Molecular Genetic Pathology Graduate Medical Education Training during COVID-19
F. El-Sharkawy Navarro

OTH04. Economic, Operational, and Clinical Considerations in Deploying Rapid NGS for Lung Cancer
C. Sande

OTH05. Study of the Critical Role Denials, Appeals, and Patient Engagement Play in the Financial Health of Pathology Practices and Molecular Laboratories
D. Richard

SOLID TUMORS

ST01. Clinical Application of oncoMonitor: A Simple ctDNA Assay for Liquid Biopsy Monitoring of Treatment and Assessment of Therapy in Colorectal and Lung Cancers
M. Minarik

ST02. Validation and Performance of Fusion Gene Panel for MiT Family Translocation Renal Cell Carcinomas: Quality of RNA Is Important for Fusion Detection
S. Harada

ST03. Testing for CDKN2A Loss in Infiltrating Gliomas Using Targeted Amplicon-Based Sequencing
E. Hissong

ST04. Long Mononucleotide Repeat Markers Improve Detection of Microsatellite Instability in Non-colorectal Cancers
J. Lin

ST05. Comprehensive Coverage of Lung Cancer Somatic Mutations by IntelliPlex Lung Cancer Panel
L. Felicioni

ST06. Assessment of Microsatellite Instability on a Multi-Racial Cohort of High Grade Prostate Cancer Using Idylla MSI Test
M. Rodriguez Pena

ST07. CANTRK: A Canadian Multi-Centre NTRK Gene Fusion Testing Validation in Solid Tumors Project
S. Martins-Filho

ST08. De-stained Cytology Smears Can Be Used for Detection of KRAS Mutations Using the Biocartis Idylla PCR-Based Molecular Diagnostic Assay
Q. Wei
ST09. A Next-Generation Sequencing Assay for Comprehensive Genomic Profiling and
Identification of Microbial Signatures in Tumor Samples
M. Yee

ST10. Assessment of PD-L1 Expression in Gastric Tumor Samples
P. Scorer

ST11. Targeted Mutational Analysis of Predictive and Prognostic Biomarkers in Colorectal
Carcinoma
G. Huang

ST12. Simultaneous Detection of Genetic and Copy-Number Variations in BRCA1/2 Genes
L. Georgieva

ST13. Analytical Performance Evaluation of TruSight Oncology 500 (TSO500) ctDNA Kit: A
Commercial Next-Generation Sequencing Liquid Biopsy Platform
S. Verma

Project
H. Jung

ST15. Validation of a Comprehensive, Targeted Next-Generation Sequencing Panel for Solid
Tumors
E. Barrie

ST16. MammaPrint and BluePrint Next-Generation Sequencing (NGS) Results Are Robust and
Accurate for Patients with Early Stage Breast Cancer
D. Kingma

ST17. Evaluation of Three RNA Quantification Methods for Next-Generation Sequencing of
Formalin-Fixed, Paraffin-Embedded Tumor Samples
D. Chan

ST18. An Exome- and Transcriptome-Based NeXT Dx Test Enables Therapy Selection for Cancer
Patients and Offers Insight into Emerging Composite Biomarkers for Immunotherapy
J. Saldivar

ST19. A Comprehensive Approach for Detection of Known and Novel Gene Fusions with RNA
Sequencing
A. Marcovitz

ST20. Cancer-Testis Antigen Detection by Targeted RNA Sequencing
J. Conroy

ST21. WITHDRAWN

ST22. FGFR Gene Mutation Analysis in Urothelial Cancer Using the therascreen FGFR RGQ Assay
in FFPE Specimen Type
L. Cai

ST23. Development and Validation of the OncoScreen RNA Panel for the Detection of Gene
Fusions and Splice Variants in Tumors
B. Li
ST24. Benefits of Rapid Genotyping of KRAS Mutations versus NGS in Pancreatic Cyst Fluids  
A. Farahani

ST25. PIK3CA Gene Mutation Analysis in Breast Cancer Using the therascreen PIK3CA RGQ Assay in FFPE Specimen Type  
L. Cai

ST26. Detection of Microsatellite Instability Using Anchored Multiplex PCR and Next-Generation Sequencing  
R. Rogge

ST27. Clinical and Analytical Validation of the ONCO/Reveal Dx Lung and Colon Cancer Assay (O/RDx-LCCA)  
N. Lodato

ST28. Noninvasive Genomic Profiling of 113 Patients with Advanced Renal Cell Carcinoma  
E. Gedvilaite

ST29. Utilization of a Targeted Next-Generation Sequencing Assay for Assessment of Tumor Cellularity, and Genome-Wide and Gene-Specific Loss of Heterozygosity (LOH)  
M. Gupta

ST30. Highly Sensitive and Specific Analysis of PIK3CA Mutations in Formalin-Fixed, Paraffin-Embedded (FFPE) Samples Using MALDI-TOF Mass Spectrometry  
A. Sartori

ST31. Internal Validation and Performance Characteristics Using the Oncomine Precision Assay to Detect Multiple Variant Types from Solid and Liquid Biopsy Samples  
J. Schageman

ST32. Somatic Variant Analysis Using a Pan-Solid Tumor Expanded Gene Panel  
S. Deharvengt

ST33. Evaluation of a Mass Spectrometry-Based PIK3CA Mutation Assay for Predictive Breast Cancer Therapeutic Decision Making  
A. Box

ST34. Single-Cell RNA Sequencing of Childhood Medulloblastoma  
N. Willard

ST35. Identifying Prognostic and Predictive Gene Alterations in Metastatic Prostate Cancer  
E. Goyette

ST36. Validation of an NGS Panel for Pancreatic Cyst Fluid Analysis  
J. Huang

ST37. Clinical Validation of an Automated 170 Gene Panel Workflow in a CAP/CLIA Laboratory for Solid Tumors  
S. Deharvengt

ST38. An RNA Sequencing Panel for Detection of Fusions and Splice Site Variants in Solid Tumors  
D. Green
ST39. Uncovering Subsets of Non-small Cell Lung Cancer (NSCLC) Enriched in Mutations in Cytoskeletal Dynamics and DNA Repair Genes: Additive Value of Large Gene Panels for Clinical Tumor Profiling
H. Tu

ST40. Rapid qPCR Testing in the NGS Era Enables Same-Day Resulting of EGFR Mutant NSCLC
N. Z. Georgantas

ST41. Rapid Assessment of Microsatellite Instability across a Spectrum of Tumor Types Using the Idylla System
A. Momeni-Boroujeni

ST42. DNA Methylome Profiling of DNA Extracted from Archived Stained Tissue Slides for Central Nervous System Tumor Diagnostics
Z. Abdullaev

ST43. WITHDRAWN

ST44. IDH1 and IDH2 Mutations in Colorectal Cancers
M. Lin

ST45. Detection of Renal Cell Carcinoma with TFEB Amplification Using Archer FusionPlex RNASEq Gene Expression Data
S. Harada

ST46. Identification of Novel Genomic Alterations in Pineal Parenchymal Tumors
R. Ondrasik

ST47. Assessment of NTRK Alterations and TRK Inhibitor Therapy: A Single Center Experience
A. Reddy

ST48. Tumor Microbiome in Colorectal Carcinoma: Bacterial Enrichment Is Associated with Oncogenic Variants within Specific Signaling Pathways
C. Beech

ST49. NKX2-1 Gene Variants in Solid Tumors: The Spectrum and Potential Impact in Surgical Pathology Diagnosis
F. El-Sharkawy Navarro

ST50. Comprehensive Genomic Profiling of Different Subsets of Merkel Cell Carcinoma: Insights on Pathogenetic Pathways
R. DeCoste

ST51. Correlation between MMR IHC and MSI Testing for Detection of MSI-High Solid Tumors
M. Shirazi

ST52. Circulating Tumor DNA Genomic and Methylation Profiling in Advanced Non-small Cell Lung Cancer Patients
J. Qin

Y. Lo

J. Chen
ST55. Comprehensive Genomic Profiling in Patients with Advanced Cancer in a Large US Healthcare System
   B. Piening

ST56. Development of Quality Control Reference Materials for Microsatellite Instability (MSI) Testing
   C. Huang

ST57. Mutated Allele Frequency and NRAS Mutational Status Are Significantly Associated with High-Risk Prognosis by 31-Gene Expression Profile
   F. Monzon

ST58. Genomic Profiling Uncovers Mutation Signatures That Differentiate Pediatric Rhabdomyosarcoma (RMS) Subgroups and Predict Clinical Outcomes
   F. Lin

ST59. Detection of Actionable Alterations in Breast and Ovarian Tumor Tissues by Testing with a 50-gene NGS Panel
   C. Ma

ST60. Microsatellite Instability Testing for Lynch Syndrome Screening in Colorectal Adenomas
   A. Javanbakht

ST61. Detection and Interpretation of Canonical and Cryptic Splice Sites in Solid Tumors and Their Relevance to FDA Approved Therapies and Clinical Trials
   E. Bogdanova

ST62. Co-occurrence of PTEN and TERT Mutations Predicts Poor Prognosis in Glioblastomas
   H. Chen

ST63. Gene Expression Profile of Sex Cord Stromal Cell Tumors and Their Relevance to Prognosis
   P. Bhattacharyya

ST64. Expression Profiling Reveals Novel Molecular Signature in Pleomorphic Lobular Carcinoma in situ
   E. Makhoul

ST65. Aberrant PAX3 (Paired Box Gene 3) RNA Splicing Is a Potential Marker for Diagnosis of Melanoma
   I. Kasago

ST66. Biomarker Testing for Patients with Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) in Academic and Community-Based Practices in the United States (US)
   L. Hess

ST67. Initial Tertiary Reporting Results from Personalize My Treatment (PMT): A Pan-Canadian Initiative Integrating Precision Oncology across Canada: PMT-001 Pilot Project
   M. Marques

ST68. Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Testing in Clinical Trials of Larotrectinib
   E. Rudzinski
ST69. Biomarker Testing and Overall Survival among Patients Diagnosed with Advanced or Metastatic Non-small Cell Lung Cancer
L. Hess

ST70. A Predictive Model of the Diagnostic Value of Next-Generation Sequencing-Based Genomics Testing in Patients with Advanced or Metastatic Non-small Cell Lung Cancer in the United States
P. Quon

ST71. Clinical Characteristics of RET- and NTRK-Rearranged Tumors in a Single Tertiary Cancer Center
T. Vougiouklakis

ST72. Incidence of T790M Mutation by ddPCR in Patients Progressing on First- and Second-Generation TKIs and Clinical Outcomes on Osimertinib
S. Nathany

ST73. Frequency of EGFR Mutations and ALK Expression in NSCLC in the North of México
B. Montaño Miyagui

ST74. Tissue Requirements of a Novel 27-Gene Immuno-Oncology Algorithm Measuring Tumor Microenvironment to Predict Response to Immunotherapies
T. Nielsen

ST75. Pan-Cancer Liquid Biopsy Assay for Mutation Profiling in 61 Genes by Low-Depth Sequencing
P. Hao

ST76. WITHDRAWN

ST77. Spatially Resolved Gene Expression Profiles in Human Glioblastoma
A. Hartnett

ST78. Spatially Resolved Molecular Interrogation of Triple Negative Breast Cancer
S. Williams

ST79. Quantitative Assessment of Functional Activity of Multiple Signaling Pathways in Recurrent Breast Cancer with Low to Intermediate 21 Gene Recurrence Score
L. Lin

ST80. Prospective Study Using Virtual Enrollment to Assess an RNA-FIT Assay for Non-invasive Detection of Colorectal Cancer, Advanced Adenomas, and Other Precancerous Adenomas
E. Barnell

ST81. NAB2-STAT6 Gene Fusions to Identify Primary/Metastasis Hemangiopericytoma/Solitary Fibrous Tumors
N. Singh

ST82. Development and Performance of Formalin Compromised FFPE Reference Materials
O. Clement

ST83. CNV Detection from a Multi-Cancer NGS Panel: A Single-Tube, Multiplex-PCR Based NGS with 309 Tiled Amplicons
A. LaBonte
ST84. Rapid Isolation of High-Quality Ultra-High Molecular Weight Genomic DNA from Blood, Bone Marrow Aspirates, and Fresh Frozen Human Tumors  
H. Sadowski

ST85. Novel Amplicon-Based NGS Library Preparation Protocols Compared and Evaluated across Two Sequencing Technologies  
E. Petrilli

ST86. Chromosomal Microarray Analysis of Benign Mesenchymal Tumors with RB1 Deletion  
A. Dusenbery

ST87. A Novel Nanoparticle-Based Approach to Improve Extraction of Circulating Tumor DNA (ctDNA)  
E. Williams

TECHNICAL TOPICS

TT01. Dimensionality Reduction for Noise Filtering of Big Data Sets  
E. Mahe

TT02. Molecular Profiling in Challenging Oncology Research Samples Using a Novel Library Preparation Chemistry  
H. Huang

TT03. Droplet Digital-PCR (ddPCR) as Confirmatory Method for Low Allelic Frequency Variants Detected by Manual Review of Data in Clinical NGS Testing  
W. Song

TT04. Performance Validation of Magnis BR: A Full-Automatic Capture-Based Library Preparation Platform for Next-Generation Sequencing (NGS)  
X. Wang

TT05. From Plasma to Variants: A Fully Automated Workflow Solution for Low-Frequency Variant Detection in Cell-Free DNA  
T. Barnes

TT06. Concordance of Variant Detection between the MoCha ctDNA Assay and Matched Tissue Biopsy in Non-small Cell Lung Cancer  
C. Karlovich

TT07. Reproducibility of Allelic Fractions of Genomic Variants from Colorectal and Lung Cancer Tissue Downstream of DNA Extraction  
M. Javey

TT08. Flexible and Complete Exome Next-Generation Sequencing (NGS) Solution for Variants Detection with Improved Human Exome Panel  
M. Hong

TT09. DNA Samples with Low Concentration Can Benefit from Speed Vacuum Concentration in NGS Testing  
W. Song
L. Zhang

TT11. Workflow Evaluation: Impact of Specimen Storage and Transport on ccfRNA Multiplex Analysis in Dedicated Blood Collection Tubes
T. Voss

TT12. Reference Materials for Measurable Residual Disease (MRD) Monitoring in Circulating Cell-Free DNA (ccfDNA)
Y. Königshofer

TT13. Automation of Fluorescence in situ Hybridization Processing and Digital Analysis
M. Azim

TT14. A Modified Vendor Extraction Protocol Better Preserves the Structural Integrity of Genomic DNA Extracted from FFPE Tissue
C. Artymiuk

TT15. WITHDRAWN

TT16. Detection of the Mutational Status in Colorectal Cancer from Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue
E. Haenssler

TT17. Centrifugation and RBC Lysis-Free Preparation of Blood Samples in less than 30 Minutes
C. Barr

TT18. A Complete Yet Flexible Workflow for Library Preparation and Analysis with Enhanced Error Correction for Low Input FFPE Tissue Biopsy and Circulating Tumor DNA Samples
S. Lee

TT19. Next-Day Analysis from Specimen to Variant Calling with the Genexus System
J. Gioia

TT20. Pushing the Limits of Cancer Research: An Integrated and Automatic Workflow on Ion Torrent Genexus System from Nucleic Acid Extraction to Next-Generation Sequencing
R. Cao

TT21. Analytical Performance Testing of the MoCha Circulating Tumor DNA Assay
R. Harrington

TT22. Digital PCR Paired with High-Speed AFM for Quantitation and Length Analysis of DNA Length Polymorphisms
S. Koebley

TT23. Focused-Ultrasoundation Driven High-Quality DNA and RNA Extraction and Purification from FFPE Samples
K. Amirault

TT24. Evaluating Effects of PCR Instruments and Temperature Ramp Rates to Base-Composition Bias in TruSight Oncology 500 (TSO500) Panel
W. Song
TT25. Evaluation of the Biocartis Idylla ctEGFR Mutation Assay on Samples with DNA Concentrations Insufficient for Next-Generation Sequencing (NGS)
   W. Keegan

TT26. Analysis of Simple and Complex Variants and Biomarkers for Comprehensive Genomic Profiling (CGP) of Solid Tumors and Hematologic Malignancies Using a Single NGS Workflow from FFPE and cfDNA Samples
   R. Samara

   Y. Lu

TT28. Archival FFPE and DNA Quality: Optimal Storage Time and Predictive Metrics for Next-Generation Sequencing
   V. Parimi (Parini)

TT29. Confirmation of Fusions Detected with Sequencing
   D. Jones

TT30. Development of a Universal Probe System for Droplet Digital PCR
   D. Jones

TT31. Targeting Clinically Significant “Dark” Regions of the Human Genome with High-Accuracy Long-Read Sequencing
   C. Heiner

TT32. Performance of GeoMx CTA and WTA, High-Plex, Spatial Gene Expression Profiling Tools
   K. Sorg

TT33. Standardizing Plasma ctDNA Measurements Using SNAQ-SEQ ONCO1LB Internal Controls
   S. Deharvengt

TT34. Optical Mapping Enables High-Throughput Analysis of Pathogenic Repeats
   E. Lam
Index of Authors

Abdel-Razeq, Hikmat - G10
Abdulbaki, Rami - ID13
Abdullaev, Zied - ST42
Abedtash, Hamed - ST69
Abu Jamous, Lama - G10
Acab, Allan - ST59
Accola, Molly A - ID47
Ackermann, Sarah - ID27
Adams, Emily N - ST36
Adams, Hans-Peter - TT07
Adhali, Omkar - I26
Afkhami, Michelle - ST62
Agarunov, Aaron - I22, I25, I26
Ahluwalia, Anupamjit - ID07
Ahmed, Asim A - ID53
Aizin, Arina - ID11
Akther, Farhana - ST51
Al Juhaishi, Taha - TT81
Al-Diffalha, Sameer - ST81
Al-Ghamdi, Yahya - H33, H40
Alikhan, Mir B - H31
Al-Kateb, Hussam - ST61
Allen, Chris - H12
Allen, Samantha F - ID15, ID16, ID48, ST32
Allen, Zoe - G19
Al-Turkmani, Rabie - ST37
Alves, Dennon A - ID52
Amadei, Mackenzie - ID30, ID31, ID32, ID34
Amirault, Richard - H14
Amin, Sejal - ID28
Amparo, Gilbert - TT18
Amsberry, Crystal - H28
An, Paul - I15
Anagnostou, Valsamo - I20
Anderson, Ben - ID17
Anderson, Jennifer L - ID03
Anderson, Peter G - I2
Andreas, Jon - ST20
Andruus, Bernard - G18
Anekhella, Bharath - ST56, ST82, TT12
Ang, Shu Hui - ST09
Ansari, Shahja R - H04
Antonarakis, Emmanuel S - ST04
Aoun, Patricia A - ST62
Aplenc, Richard - H24
Aran Rosainz, Manuel - ST64
Arcila, Maria E. - H03, I22, I25, ST41, ST48
Arenz, Bahram - TT18
Arias-Stella, Javier - ST62
Aryaratne, Pramila - ST09
Aro, Lori - TT31
Artyumuk, Cody J - H06, I08, TT14
Arumugam, Swakumaran Theru - G05
Arvanitis, Leonidas D - ST62
Ayeequaye, Ruth - H23
Ashmann, Jacob - G27
Askar, Medhat - ID20, ID49
Aslam, Aneoshe - ID35, ID37, ID41
Asuncion, Lawreen - ST29
Au, Kaylene - G21
Austermiller, Bradley - TT33
Au-Young, Janice - I07, ID55, ST29
Averianus, Matthew - G19, ST39
Ayash, Erin - ST18

Aye, Min Ko Ko - ID11, ST09
Aypar, Umut - G13, H23
Aziz, Mohammad - TT13
Azzato, Elizabeth - H44
Babady, Esther - ID3S, ID37, ID39, ID41, ID65, ID66, ID67, ID68
Bacher, Rowena - ID57
Badie, Behnam - ST62
Bae, Ju-Hee - ID23
Baek, Iii - TT03, TT05, TT09, TT24
Bagatell, Rochelle - ST14, ST58
Bagg, Adam - OTH02
Bagi, Lori K - ID55
Bailey, Michael - ID38
Baisre-de leon, Ada - H30
Balakrishnan, Anoop - I25, I26
Balan, Jagadiksethru - H96, I08
Ball, David - ST55
Banda, Santosh - ST29
Bao, Jing - TT13
Bapat, Bel - ST55
Baptiste, Milshauna - ID07
Barbee, Jada - ST41
Barboza, Oraia - ST73
Bardakjian, Tonya - G16
Barker, Craig - ST10
Barnell, Andrew R - ST80
Barnell, Erica K - ST80
Barnes, Timothy - TT02, TT05
Barney, Rachael E - ID21, ID51
Bar, Christine - TT17
Barrick, Brian - I06, ST15
Barrie, Elizabeth - I06, ST15
Bask, Michael - I03
Basu, Malay K - I16
Basu, Shubham - H66, I08
Balist, Gerald - ST67
Baltra, Ullas - ST72
Baugh, Laura - H43
Baynak-Toydemir, Pinar - G05, G08, G15
Bee, Gary G - ST19
Beech, Cameron - ST48
Beechem, Joseph - ID38, TT32
Behling, Kathryn C - OTH01
Bell, Drow A - ID54
Belsanova, Barbora - ST01
Benavides, Raul - ID20, ID49
Benayed, Ryama - H03, I25, ST28
Benesova, Lucie - ST01
Benoit, Jeanne - ST26
Bent, Zachary - ST77, ST78
Berg, Susan Z - G12
Berger, Michael F - ST28
Berman, David - ST07
Berman, Diana - ID40
Bertuch, Alison A - H04
Bettiegowda, Chetan - H14
Beyrer, Julie K - ST69
Bhandari, Ambika - G01
Bhandari, Naleen R - ST70
Bhattacharyya, Prithi K - ST63
Bili, Tengteng - I11
Bickford, Michelle A - TT13
Biegel, Jaclyn A - G02
Biery, Nancy - ST55
Bifulco, Carlo - ST55
Bigras, Gilbert - ST07
Bisoy, Ozge - I26
Blüher, Anja - TT07
Black, Margaret - ST79
<table>
<thead>
<tr>
<th>Name</th>
<th>ID/ST/T2/T12/H44</th>
<th>Name</th>
<th>ID/ST/T2/T12/H44</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blair, Amanda</td>
<td>ID36</td>
<td>Chang, Jayde</td>
<td>H17, H19</td>
</tr>
<tr>
<td>Blair, Lily</td>
<td>ID53</td>
<td>Chang, Ting-Chia</td>
<td>TT06, TT21</td>
</tr>
<tr>
<td>Blake, Drew</td>
<td>H10</td>
<td>Chatterjee, Sharmila</td>
<td>ST77, ST78</td>
</tr>
<tr>
<td>Blauwkamp, Timothy A</td>
<td>ID53</td>
<td>Chaudhuri, Adel A</td>
<td>ST80</td>
</tr>
<tr>
<td>Blombery, Piers</td>
<td>H37</td>
<td>Cheang, Gloria</td>
<td>ST03, TT03, TT09, TT24</td>
</tr>
<tr>
<td>Bockelman, Daniel</td>
<td>I27</td>
<td>Chebib, Ivan</td>
<td>ID25</td>
</tr>
<tr>
<td>Boeckh, Michael</td>
<td>ID53</td>
<td>Chellappan, Ajithavalli</td>
<td>I09</td>
</tr>
<tr>
<td>Boese, Krystal</td>
<td>ID03</td>
<td>Chen, Alice P</td>
<td>TT21</td>
</tr>
<tr>
<td>Bogdanova, Ekaterina</td>
<td>ST61</td>
<td>Chen, Chin-Tung</td>
<td>ST48</td>
</tr>
<tr>
<td>Bootwalla, Moiz S</td>
<td>G02</td>
<td>Chen, Derrick J</td>
<td>ID47</td>
</tr>
<tr>
<td>Borczuk, Alain</td>
<td>ID38, ID40</td>
<td>Chen, Dong</td>
<td>H39</td>
</tr>
<tr>
<td>Borsu, Laetitia</td>
<td>H03, I25</td>
<td>Chen, Gloria</td>
<td>ST27</td>
</tr>
<tr>
<td>Bossler, Aaron D</td>
<td>H07</td>
<td>Chen, Hsiao-Wei</td>
<td>ST62</td>
</tr>
<tr>
<td>Bowman, Anita</td>
<td>ST48</td>
<td>Chen, Jade</td>
<td>ID07</td>
</tr>
<tr>
<td>Box, Adrian</td>
<td>ST07, ST33</td>
<td>Chen, Je-Fu</td>
<td>ID56, ST54</td>
</tr>
<tr>
<td>Boyananapalli, Ramakrishna</td>
<td>G18</td>
<td>Chen, Jonathan H</td>
<td>ID25</td>
</tr>
<tr>
<td>Boyd, David C</td>
<td>I12</td>
<td>Chen, Keith</td>
<td>TT18</td>
</tr>
<tr>
<td>Boyle, Theresa</td>
<td>ST65</td>
<td>Chen, Lei</td>
<td>TT04</td>
</tr>
<tr>
<td>Bradley, Eliza</td>
<td>ID15, ST60, TT25</td>
<td>Chen, Li</td>
<td>TT06, TT21</td>
</tr>
<tr>
<td>Bram, Yaron</td>
<td>ID38</td>
<td>Chen, Liam</td>
<td>ST44</td>
</tr>
<tr>
<td>Bramlett, Kelli S</td>
<td>ST31, TT20</td>
<td>Chen, Miaomiao</td>
<td>ST52</td>
</tr>
<tr>
<td>Brecklin, Dana</td>
<td>ID14</td>
<td>Chen, Mingyi</td>
<td>H38</td>
</tr>
<tr>
<td>Briggs, Benjamin</td>
<td>ID45</td>
<td>Chen, Richard</td>
<td>ST18</td>
</tr>
<tr>
<td>Broadfoot, Brannon</td>
<td>ID50</td>
<td>Chen, Rong</td>
<td>ST61</td>
</tr>
<tr>
<td>Brodeur, Garrett</td>
<td>ST58</td>
<td>Chen, Suping</td>
<td>ST04</td>
</tr>
<tr>
<td>Byron, Alexandra L</td>
<td>ID33</td>
<td>Chen, Tzu-Chun</td>
<td>TT02, TT05</td>
</tr>
<tr>
<td>Buchanan, Blake W</td>
<td>ID01</td>
<td>Chen, Weina</td>
<td>H22, H25, H38</td>
</tr>
<tr>
<td>Buchan, Jillian G</td>
<td>G05, G08</td>
<td>Chen Wongworawat, Yan</td>
<td>H10</td>
</tr>
<tr>
<td>Buillard, Brian</td>
<td>I06, ST15</td>
<td>Chen, Xiang</td>
<td>H44</td>
</tr>
<tr>
<td>Burgher, Blake</td>
<td>ST20</td>
<td>Cheng, Angie</td>
<td>TT19, TT20</td>
</tr>
<tr>
<td>Burke, Jennifer</td>
<td>ID55</td>
<td>Chenn, Anjen</td>
<td>ST22, ST25</td>
</tr>
<tr>
<td>Burnham, Carey-Ann</td>
<td>ID01</td>
<td>Cherabuddi, Kartik</td>
<td>ID45</td>
</tr>
<tr>
<td>Butler, Joseph</td>
<td>ID10</td>
<td>Chesney, Alden</td>
<td>TT22</td>
</tr>
<tr>
<td>Butler, Mathew G</td>
<td>ST56, TT12</td>
<td>Cheung, Carol</td>
<td>ST07</td>
</tr>
<tr>
<td>Butitta, Fianna</td>
<td>ST05</td>
<td>Chevarie-Davis, Myriam</td>
<td>ST07</td>
</tr>
<tr>
<td>Cadou, Karen</td>
<td>G13</td>
<td>Chew, Jennifer</td>
<td>ST77, ST78</td>
</tr>
<tr>
<td>Cai, Gracie</td>
<td>H03</td>
<td>Chieda, Pratiksha</td>
<td>ID12</td>
</tr>
<tr>
<td>Cai, Li</td>
<td>ST22, ST25</td>
<td>Chinnappa, Manju</td>
<td>ST18</td>
</tr>
<tr>
<td>Calderwood, Michael S</td>
<td>ID43</td>
<td>Chiu, Alle</td>
<td>H39</td>
</tr>
<tr>
<td>Calio, Anna</td>
<td>ST02, ST45</td>
<td>Chiu, Jonathan</td>
<td>H39</td>
</tr>
<tr>
<td>Campan, Mihaela</td>
<td>I03</td>
<td>Cho, Hee Won</td>
<td>ID58</td>
</tr>
<tr>
<td>Campbell, Andrew</td>
<td>G07, H45</td>
<td>Choi, Leno</td>
<td>TT28</td>
</tr>
<tr>
<td>Campbell, Mary</td>
<td>ST55</td>
<td>Chu, Clement</td>
<td>G23</td>
</tr>
<tr>
<td>Cantu, Erin</td>
<td>TT06</td>
<td>Chu, Quincy</td>
<td>TT10</td>
</tr>
<tr>
<td>Cantu, Miguel D</td>
<td>H21</td>
<td>Church, Melissa</td>
<td>G18</td>
</tr>
<tr>
<td>Cao, Kaja</td>
<td>H24, ST58</td>
<td>Citrón, Melvini</td>
<td>ID68</td>
</tr>
<tr>
<td>Cao, Ru</td>
<td>ST31, TT19, TT20</td>
<td>Clark, Michael J</td>
<td>ST18</td>
</tr>
<tr>
<td>Caradonna, Ippolito</td>
<td>ID57</td>
<td>Clay, Mike</td>
<td>H44</td>
</tr>
<tr>
<td>Carbone, David</td>
<td>ST39</td>
<td>Clement, Omoshile</td>
<td>ST56, ST82, TT12</td>
</tr>
<tr>
<td>Carlo, Maria</td>
<td>G13</td>
<td>Clyde, Karen</td>
<td>ID05</td>
</tr>
<tr>
<td>Carpenter, Meredith L</td>
<td>ID57</td>
<td>Cody, Maria</td>
<td>ID19</td>
</tr>
<tr>
<td>Carpenter, Stephanie</td>
<td>ST12</td>
<td>Coffin, John</td>
<td>TT10</td>
</tr>
<tr>
<td>Carter, Michael D</td>
<td>ST50</td>
<td>Collingwood, Robin</td>
<td>ST81</td>
</tr>
<tr>
<td>Carter, Theodore</td>
<td>ID57</td>
<td>Columbus, Cristie</td>
<td>ID49</td>
</tr>
<tr>
<td>Caruthers, Sean</td>
<td>ST39</td>
<td>Cong, Lin</td>
<td>ID27, ID29, ID40</td>
</tr>
<tr>
<td>Castano Gonzalez, Luis Antonio</td>
<td>I07</td>
<td>Conley, Kelsey</td>
<td>TT21</td>
</tr>
<tr>
<td>Castro, Allan J</td>
<td>ID05, ID06</td>
<td>Conner, Kayla L</td>
<td>ST29</td>
</tr>
<tr>
<td>Casuga, Iris</td>
<td>TT19</td>
<td>Conroy, Jeffrey</td>
<td>ST20</td>
</tr>
<tr>
<td>Catalano, Jeffrey</td>
<td>I23, I27, TT03, TT09</td>
<td>Cook, Leanne J</td>
<td>ID16, ID48</td>
</tr>
<tr>
<td>Catanese, Joseph</td>
<td>ID17</td>
<td>Cook, Robert</td>
<td>ST57</td>
</tr>
<tr>
<td>Cermelli, Silvia</td>
<td>ID02</td>
<td>Cooper, Lauren A</td>
<td>ID54</td>
</tr>
<tr>
<td>Ceyhan-Birsoy, Ozge</td>
<td>G11, G13</td>
<td>Copeland, Sarah</td>
<td>G19</td>
</tr>
<tr>
<td>Chadburn, Amy</td>
<td>H21</td>
<td>Cotter, Philip</td>
<td>G01, ST13</td>
</tr>
<tr>
<td>Chakravarty, Debyani</td>
<td>ST48</td>
<td>Cotzi, Paolo</td>
<td>ST71, ST79</td>
</tr>
<tr>
<td>Chan, Bob</td>
<td>ST16</td>
<td>Couetoux du Tertre, Mathilde</td>
<td>ST67</td>
</tr>
<tr>
<td>Chan, Danny</td>
<td>ST17</td>
<td>Covington, Kyle</td>
<td>ST57</td>
</tr>
<tr>
<td>Chan, Emily</td>
<td>TT27</td>
<td>Coyle, Sabrina</td>
<td>ID09</td>
</tr>
<tr>
<td>Chan, Roger</td>
<td>H03, ST41</td>
<td>Craney, Aryn</td>
<td>ID27, ID29</td>
</tr>
<tr>
<td>Chang, Chung-Ché</td>
<td>H28</td>
<td>Craven, Kelly E</td>
<td>I04</td>
</tr>
<tr>
<td>Cremona, Maria Laura</td>
<td>G05, G08</td>
<td>Cremona, Maria Laura</td>
<td>G05, G08</td>
</tr>
<tr>
<td>Name</td>
<td>ID or ST</td>
<td>Name</td>
<td>ID or ST</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------</td>
<td>-------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Moncur, Joel T</td>
<td>ID52</td>
<td>Monroe, Robert</td>
<td>ID25</td>
</tr>
<tr>
<td>Montañez, Benjur Y</td>
<td>ST73</td>
<td>Montgomery, Nathan</td>
<td>ID59</td>
</tr>
<tr>
<td>Monzon, Federico</td>
<td>ST57</td>
<td>Mook, Jennifer</td>
<td>ID14</td>
</tr>
<tr>
<td>Moore, Franklin</td>
<td>ID64</td>
<td>Moore, Mathew</td>
<td>G01, ST13</td>
</tr>
<tr>
<td>More, Christopher</td>
<td>ID19</td>
<td>Morlote, Diana</td>
<td>H41, I16,ST02,ST45</td>
</tr>
<tr>
<td>Morra, Massimo</td>
<td>ST18</td>
<td>Morris, Luc</td>
<td>ID65</td>
</tr>
<tr>
<td>Morre, Philip N</td>
<td>G03</td>
<td>Motzer, Robert</td>
<td>ST28</td>
</tr>
<tr>
<td>Moyer, Krista</td>
<td>G26</td>
<td>Mroz, Pawel</td>
<td>H42</td>
</tr>
<tr>
<td>Mullet, Kristen</td>
<td>ST63</td>
<td>Muley, Thomas</td>
<td>I-17</td>
</tr>
<tr>
<td>Murdoch, Kasinathan</td>
<td>G15</td>
<td>Murray, Rebecca</td>
<td>I26</td>
</tr>
<tr>
<td>Murray, Samuel J</td>
<td>ST28</td>
<td>Mustafa, Asma</td>
<td>I-14</td>
</tr>
<tr>
<td>Muzzey, Dale</td>
<td>G23</td>
<td>Myrand, Scott P</td>
<td>ST19</td>
</tr>
<tr>
<td>Nadaoleski, Krista</td>
<td>OTH05</td>
<td>Nael, Theodore</td>
<td>ST13</td>
</tr>
<tr>
<td>Nath, Khoudjia</td>
<td>ST42</td>
<td>Nair, Shilpa</td>
<td>I09</td>
</tr>
<tr>
<td>Nakatandwe, Joy</td>
<td>H44</td>
<td>Namiki, Steven</td>
<td>G21</td>
</tr>
<tr>
<td>Naser, Wald</td>
<td>G10</td>
<td>Naata, Sunita</td>
<td>OTH02</td>
</tr>
<tr>
<td>Nathany, Shrinidh</td>
<td>ST72</td>
<td>Neafie, Fides</td>
<td>ID52</td>
</tr>
<tr>
<td>Neafie, Ronald</td>
<td>ID52</td>
<td>Neary, Jennifer</td>
<td>H44</td>
</tr>
<tr>
<td>Neerken, Sigi</td>
<td>ST79</td>
<td>Neff, Jadee L</td>
<td>H13</td>
</tr>
<tr>
<td>Nelson, Ann M</td>
<td>ID52</td>
<td>Nepomuceno-Perez, Mia</td>
<td>H10</td>
</tr>
<tr>
<td>Neron, Robert d</td>
<td>ID36</td>
<td>Netto, George J</td>
<td>ST02,ST06,ST45</td>
</tr>
<tr>
<td>Newman, Erin</td>
<td>ST18</td>
<td>Newman, Scott</td>
<td>H44, ST61</td>
</tr>
<tr>
<td>Neyaz, Azfar</td>
<td>ID25</td>
<td>Ng, David</td>
<td>H32</td>
</tr>
<tr>
<td>Ng, David</td>
<td>H32</td>
<td>Ng, Ivan</td>
<td>ID11</td>
</tr>
<tr>
<td>Nguyen, Karen</td>
<td>TT32</td>
<td>Nguyen, Lequan</td>
<td>ST56</td>
</tr>
<tr>
<td>Nguyen, Trang</td>
<td>ST90</td>
<td>Nguyen, Trinh</td>
<td>ID30, ID31,ID32,ID34</td>
</tr>
<tr>
<td>Niccum, Brittany</td>
<td>TT05</td>
<td>Nichols, Kim E</td>
<td>H44</td>
</tr>
<tr>
<td>Nielsen, Tyler J</td>
<td>ST74</td>
<td>Nielsen, Tyler J</td>
<td>ST74</td>
</tr>
<tr>
<td>Niemann, Linda T</td>
<td>ID26</td>
<td>Nightingale, Mathew</td>
<td>ST50</td>
</tr>
<tr>
<td>Nikolic, Dejan</td>
<td>ID28</td>
<td>Nogai, Hendrik</td>
<td>ST68</td>
</tr>
<tr>
<td>Norgaard, Zach</td>
<td>TT32</td>
<td>Novak, Barbara</td>
<td>TT18</td>
</tr>
<tr>
<td>Ntiamoah, Peter</td>
<td>H23</td>
<td>Nyirenda, Thembisa</td>
<td>ST63</td>
</tr>
<tr>
<td>Oakley, Joel</td>
<td>I-23</td>
<td>Oehninger, Margret</td>
<td>ID02</td>
</tr>
<tr>
<td>Offit, Kenneth</td>
<td>G11, G13</td>
<td>Oldakowski, Mark</td>
<td>ST84, TT34</td>
</tr>
<tr>
<td>Oh, WonJun</td>
<td>ID24</td>
<td>Oliver, Dwight</td>
<td>H20, H38</td>
</tr>
<tr>
<td>Olson, Damon</td>
<td>ID04</td>
<td>Olson, Gwyneth</td>
<td>G27</td>
</tr>
<tr>
<td>Olson, Thomas</td>
<td>ST15</td>
<td>O’Neil, Terri</td>
<td>H44</td>
</tr>
<tr>
<td>Ondraski, Regina</td>
<td>ST46</td>
<td>Ong, Thaddeaus</td>
<td>ST09</td>
</tr>
<tr>
<td>Ostman, Emily</td>
<td>ID44</td>
<td>O’Sullivan Couye, Geraldine Helen</td>
<td>TT21</td>
</tr>
<tr>
<td>Pabla, Sarayor</td>
<td>ST20</td>
<td>Paban, Carlos</td>
<td>TT18</td>
</tr>
<tr>
<td>Pagani, Ioanna</td>
<td>ID18</td>
<td>Pallavajala, Aparna</td>
<td>I04, I20,ST36,ST44</td>
</tr>
<tr>
<td>Palma, John</td>
<td>I-17</td>
<td>Palmer, Jill E</td>
<td>ID47</td>
</tr>
<tr>
<td>Palmier, Stuari</td>
<td>ST05</td>
<td>Pan, Xiaokang</td>
<td>ST39</td>
</tr>
<tr>
<td>Parakh, Shilpa</td>
<td>ST05</td>
<td>Pareja, Fresia</td>
<td>G11</td>
</tr>
<tr>
<td>Park, Eva</td>
<td>ST03</td>
<td>Parini (Parini), Vamsi</td>
<td>TT28</td>
</tr>
<tr>
<td>Park, Hyeon Jin</td>
<td>I23, TT03,TT09,TT24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park, Jeong Su</td>
<td>ID58</td>
<td>Park, Paul</td>
<td>ST07</td>
</tr>
<tr>
<td>Park, Paul</td>
<td>ST07</td>
<td>Parker, Connor</td>
<td>G27</td>
</tr>
<tr>
<td>Pasternak, Sylvia</td>
<td>ST50</td>
<td>Patel, Darshana</td>
<td>G18, G29</td>
</tr>
<tr>
<td>Patel, Johan</td>
<td>I10</td>
<td>Patel, Keyur P.</td>
<td>H36</td>
</tr>
<tr>
<td>Patel, Utsav</td>
<td>ST41</td>
<td>Paidar, Rajesh</td>
<td>TT21</td>
</tr>
<tr>
<td>Patro, Jagannath</td>
<td>I09</td>
<td>Patterson, Sara</td>
<td>I21</td>
</tr>
<tr>
<td>Patterson, Taylor</td>
<td>ST26</td>
<td>Paulraj, Prabakaran</td>
<td>I06, ST15</td>
</tr>
<tr>
<td>Pavenko, Anna</td>
<td>TT32</td>
<td>Peach, Amanda</td>
<td>TT06, TT21</td>
</tr>
<tr>
<td>Pedroza, Anthony</td>
<td>TT20</td>
<td>Pencreach, Erwan</td>
<td>ST30</td>
</tr>
<tr>
<td>Pennington, Rod</td>
<td>ID14</td>
<td>Perizzolo, Marco</td>
<td>H15, ST33</td>
</tr>
<tr>
<td>Pepe, Milos</td>
<td>ST01</td>
<td>Peters, Carrie</td>
<td>TT17</td>
</tr>
<tr>
<td>Peters, Sengers</td>
<td>Hessel</td>
<td>Peters, Matthew</td>
<td>ID45</td>
</tr>
<tr>
<td>Petitt, Matthew</td>
<td>ID45</td>
<td>Petrill, Erin</td>
<td>G30, ST83,ST85</td>
</tr>
<tr>
<td>Petruzelika, Lubos</td>
<td>ST01</td>
<td>Petersson, Jonas</td>
<td>I03</td>
</tr>
<tr>
<td>Petterson, Jonas</td>
<td>I03</td>
<td>Pettus, Jason</td>
<td>ST35</td>
</tr>
<tr>
<td>Pfifer, John</td>
<td>G05, G08, ID56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pham, Ha T</td>
<td>G15</td>
<td>Pham, Khoo</td>
<td>ST84</td>
</tr>
<tr>
<td>Philkana, Deepika</td>
<td>ST82</td>
<td>Pilee, Loni</td>
<td>H17, H19</td>
</tr>
<tr>
<td>Piening, Brian D</td>
<td>ST55</td>
<td>Pillai, Raju K</td>
<td>ST02</td>
</tr>
<tr>
<td>Pilz, Joseph</td>
<td>ID07</td>
<td>Pindikuri, Shwetha</td>
<td>ST55</td>
</tr>
<tr>
<td>Pinto, Christopher J</td>
<td>ID25</td>
<td>Pitsapia, David J</td>
<td>I23, ST03</td>
</tr>
</tbody>
</table>
Zmuda, Erik - G26
Zou, Denise - ST70
Zuo, Zhuang - H38
Explore The Virtual Expo Hall

Expo Hall

Be sure not to miss the Virtual Expo Hall - whether you're searching for the latest products and services, are just browsing, or want to connect with one of your current vendors, the AMP Expo Hall has it all! Once in the Virtual Platform, please enter the "Expo Hall" You'll be able to search the "exhibitor index" or scroll through to see booths from AMP Corporate Partners and exhibiting companies.

DON'T MISS THESE EXCITING FEATURES OF THE VIRTUAL EXPO HALL:

- Reserve your "Chat Slot" with Premium Exhibitors during the designated Expo Hall hours.
- Save exhibitor documents to your "Virtual Meeting Bag" and email them to yourself later.
- Participate in the "Scavenger Hunt" in the Expo Hall and the "AMP Leaderboard" throughout the virtual platform! We have some really cool prizes - check them out on the "Leaderboard" menu tab in the Lobby!

Meet the AMP 2020 Exhibitors

Explore the virtual AMP Expo Hall and meet over 80 exhibiting companies!
Take a few moments to peruse the list of exhibitors found in the online listing. You can also read about this year’s exhibitors in the meeting program. You are encouraged to also engage and interact with exhibitors during the interactive Expo Hall hours:

Interactive Expo Hall Hours

Monday, November 16, 2020
10:30am - 11:15am
2:00pm - 3:00pm - includes demos & drawings

Tuesday, November 17, 2020
11:00am - 11:45am
2:00pm - 3:00pm - includes demos & drawings

Wednesday, November 18, 2020
11:00am - 11:45am
2:30pm - 3:30pm - includes demos & drawings

Thursday, November 19, 2020
11:00am - 11:45am
2:00pm - 3:00pm - includes demos & drawings

Friday, November 20, 2020
11:00am - 11:45am
2:30pm - 3:30pm - includes demos & drawings
AMP 2020 Annual Meeting & Expo Exhibitors

10x Genomics
AccuGenomics, Inc
**Adaptive Biotechnologies Corp.***
Agena Bioscience
Agendia
Agilent Technologies
Amoy Diagnostics Co., Ltd.
Applied BioCode, Inc.
Arc Bio LLC
**ArcherDx***
**AstraZeneca***
**Asuragen***
ATCC
Bangs Laboratories
**Bayer Healthcare***
Biocartis
Bionano Genomics
Bio-Rad Laboratories, Inc.
Burning Rock Dx
Caris Life Sciences
Cepheid
ChromaCode
CLINICAL LAB PRODUCTS
Clinical Omics
COMBiNATi
Canexia Health
Covaris, Inc.
DiaSorin Molecular
**Eli and Lilly Company***
Fabric Genomics
Fidelis Research
Foundation Medicine, Inc.
Genentech
GenMark Diagnostics
GenomeWeb
GlaxoSmithKline
Hamilton Company
**Hologic***
IDbyDNA
**Illumina***
Integrated DNA Technologies
Invivoscribe
LGC, Biosearch Technologies
LGC SeraCare
Life Magnetics
Luminex
Maine Molecular Quality Controls, Inc.
Menarini Silicon Biosystems
**Merck***
Meridian BioScience Inc.
MetaSystems Group, Inc.
MilliporeSigma
Mission Bio
NanoString Technologies
NeoGenomics Laboratories
New England Biolabs
Novartis Oncology
Omega Bio-Tek, Inc.
Ovation.io
Oxford Gene Technology
Paragon Genomics, Inc.
PCR Biosystems
PerkinElmer
Personal Genome Diagnostics
Personalis
PierianDx
Pillar Biosciences Inc.
PlexBio Co., Ltd
Promega Corporation
Purigen Biosystems, Inc.
QIAGEN
Quantabio
Rheonix, Inc.
Roche***
SoftGenetics, LLC
Sophia Genetics
STEMCELL Technologies, Inc.
Streck
**Takeda***
Tempus
The Jackson Laboratory
The Pathologist
**Thermo Fisher Scientific***
Twist Bioscience
Vela Diagnostics
Zymo Research Corp.

*Corporative Partners
10x Genomics
Website: http://www.10xgenomics.com
Email: theresa.craw@10xgenomics.com
10x Genomics builds solutions to interrogate biological systems at a resolution and scale that matches the complexity of biology. Our rapidly expanding suite of products, which include instruments, consumables, and software, have enabled customers to make fundamental discoveries across multiple research areas, including cancer, immunology, and neuroscience.

AccuGenomics, Inc.
http://www.accugenomics.com
nlazaridis@accugenomics.com
AccuGenomics manufactures custom Mixtures of Internal Standards (MIS™) that enable new levels of scientific integrity and eliminates all false positives from any targeted NGS method. Our SNAQ technology provides the best in class Accuracy, Specificity, and Limits of Detection for measuring multiple targets by qPCR (SNAQ-PCR) and NGS (SNAQ-SEQ). Treat patients right the first time! Our Standards Your Quality

COPRARET PARTNER
Adaptive Biotechnologies Corp.
https://www.adaptivebiotech.com/
clinicals@adaptivebiotech.com
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery.

Agena Bioscience
http://agenabio.com
mickie.henshall@agenabio.com
We Empower Precision Medicine. Agena Bioscience enables clinical laboratories worldwide to deliver affordable targeted genomic testing. Our easy to use mid-plex diagnostic platforms deliver fast, accurate and actionable results, to aid in clinical decision making and improve laboratory economics..

Agenda
22 Morgan
https://www.agendia.com/
dina.scaglione@agenda.com
Agenda is a precision oncology company headquartered in Irvine, California, committed to bringing early-stage breast cancer patients and their physicians the information they need to make the most effective treatment decisions. The company currently offers two commercially-available genomic profiling tests, supported by clinical and real-world evidence. MammaPrint®, the 70-gene breast cancer recurrence assay, and BluePrint®, the 80-gene molecular subtyping assay, provide a comprehensive genomic profile and the data physicians need to make more informed decisions in the pre- and post-operative treatment settings. By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat cancer, Agenda aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis

Agilent Technologies
http://www.agilent.com
inquiries@agilent.com
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.

Amoy Diagnostics Co., Ltd.
http://Amoy Diagnostics, Co., Ltd.
thruykuang@amoydx.com
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based manufacturer of genetic testing products and diagnostic service provider for precision oncology. Our mission is to provide our customers with superior and innovative products and services to improve healthcare and patients’ lives.

Applied BioCode, Inc.
http://www.apbiocode.com/
biz-development@apbiocode.com
Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The company has combined “digital barcodes” with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets. The company is FDA-510K cleared for their Respiratory 17-plex Pathogen Panel and Gastrointestinal 17-plex Pathogen Panel based on their BioCode® MDx-3000 automated system. Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.

Arc Bio LLC
http://www.arcbio.com
info@arcbio.com
Arc Bio is revolutionizing pathogen detection by developing novel NGS solutions that allow for fast, precise, and cost-effective analysis. Our mission is to transform how infectious disease is diagnosed, treated, and managed. The Galileo™ product line arms physicians and laboratorians with an entirely new standard for infectious disease detection through an integrated set of easy-to-use, cutting-edge genomic tools.
**CORPORATE PARTNER**

**ArcherDX**
https://archerdx.com/
pbalsley@archerdx.com

ArcherDX advances molecular pathology with a robust technology platform for NGS-based genetic mutation detection. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.

**CORPORATE PARTNER**

**AstraZeneca**
https://www.astrazeneca.com
alyssa.u@astrazeneca.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection.

**CORPORATE PARTNER**

**Asuragen**
https://asuragen.com
ecalver@asuragen.com

Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms.

**ATCC**
http://atcc.org
adowning@atcc.org

Scientific progress depends on a strong foundation of credibility. As the leading global provider of credible biological products including biological standards and reference materials, ATCC is committed to supporting the AMP community with standards and solutions needed to make incredible achievements in oncology and infectious disease testing, molecular assay development and microbiome research. Visit booth #2852 to discover more. www.atcc.org

**Bangs Laboratories**
http://www.bangslabs.com
amy@bangslabs.com

Manufacturer of magnetic, silica and polymer microparticles used as critical raw materials for clinical and molecular biology applications such as sample prep, nucleic acid isolation, sequencing and PCR.

**CORPORATE PARTNER**

**Bayer Healthcare**
http://www.bayer.us.com
bridget.lewis@bayer.com

Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.

**Biocartis**
http://www.biocartis.com/us
customerserviceUS@biocartis.com

Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, PCR based system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. For more information, visit our website at www.biocartis.com/us

**Bionano Genomics**
http://bionanogenomics.com
wobannon@bionanogenomics.com

Bionano Genomics, Inc. is a life sciences company in the genome analysis space. Bionano develops and markets the Saphyr® system, a digital cytogenetics platform for genome-wide detection of all structural variant types in cancer and germline/constitutional samples that enables researchers to accelerate the search for new diagnostics and therapeutic targets. To learn more, please visit: www.BionanoGenomics.com.

**Bio-Rad Laboratories, Inc.**
https://www.bio-rad.com
sonya_sano@bio-rad.com

Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Bio-Rad is committed to bringing innovative molecular diagnostic tools to the market with our Droplet Digital PCR, Real-Time PCR, and Molecular Control solutions.

**Burning Rock Dx**
https://brbiotech.com/
Tom.Li@brbiotech.com

Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.
Caris Life Sciences
https://www.carislifesciences.com/
corpcomm@carisls.com
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. To learn more, please visit www.CarisLifeSciences.com.

Cepheid
http://www.cepheid.com
arshia.hussain@cepheid.com
Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way to perform sophisticated genetic testing for organisms and genetic-based diseases. The company is focusing on those applications where accurate, rapid, and actionable test results are needed most.

ChromaCode
http://www.chromacode.com
spowell@chromacode.com
ChromaCode is redefining molecular testing through data science. ChromaCode’s HDPCR™ multiplexing technology couples widely-used, low-cost chemistries with proprietary software to empower the global installed base of qPCR/dPCR instrumentation to perform multiplex testing at a very low cost. Using HDPCR™, ChromaCode is seeking to expand global access to multiplex testing, reduce healthcare costs, and provide solutions for unmet healthcare needs faster.

CLINICAL LAB PRODUCTS
http://www.CLPmag.com
timo@medqor.com
For more than 50 years, Clinical Lab Products continues to be the preeminent product and technology publication for the clinical laboratory community. The CLP portfolio includes a glossy trade publication that presents feature articles, interviews, product news, and comparative Tech Guides (10x annually), plus a print and online Buyers Guide, webcasts, e-newsletters, white papers, and website—all with a focus on the specialized products and technologies used in clinical laboratories. For a FREE subscription, please reach out to us or visit: CLINICAL LAB PRODUCTS

Clinical Omics
http://www.clinicalomics.com
smccarthy@liebetpub.com
Clinical OMICs is the leading source of practical insights for pathologists, clinicians, researchers, and scientists working to translate important findings across the broad range of "omics" technologies to deliver on the promise of molecular and precision medicine for patients.

COMBINATi
http://www.combinati.com
adam.langston@combinati.com
COMBINATi believes simplicity shouldn’t require sacrificing robustness, quality or rigor – in fact, it should enable it. Our easy-to-use digital PCR platform offers absolute quantification to track disease-relevant biomarkers over time with high accuracy and precision. Comprised of a single instrument and a single consumable, COMBINATi aims to democratize digital PCR for researchers all over the world.

Canexia Health (Contextual Genomics)
http://www.contextualgenomics.com
efarrag@contextualgenomics.com
Canexia Health (formerly Contextual Genomics) makes high quality cancer genomic information accessible with our clinically-validated assays, informatics and support. Our suite of genomics-based cancer tests is clinically actionable and cost-effective, designed to improve cancer treatment and monitoring. With our extensive scientific expertise, specialized genomics-based tests, and support from pharmaceutical and diagnostics partners, we are leading the shift towards precision oncology.

Covaris, Inc.
http://www.covaris.com
info@covaris.com
Covaris is the recognized industry leader in NGS, utilizing its patented Adaptive Focused Acoustics® (AFA®) technology for DNA fragmentation. AFA-energetics™ is also used for a wide range of sample preparation applications including FFPE and cfDNA extraction, chromatin shearing, proteomics, epigenomics, cell lysis, and compound management. Please visit www.covaris.com for more information.

DiaSorin Molecular
http://molecular.diasorin.com
marketing-info_molecular@diasorin.com
DiaSorin Molecular manufactures and distributes molecular diagnostic products worldwide helping laboratories to streamline workflow and improve patient management. Our Simplexa® molecular kits include HSV-1 & 2, Flu A/B & RSV, Bordetella, VZV, Group A Strep, Group B Strep, and C. difficile. Additionally, our menu includes over 60 primer pairs for laboratory-developed tests.

CORPORATE PARTNER
Eli and Lilly Company
www.LillyOncology.com
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
Fabric Genomics
http://www.fabricgenomics.com
info@fabricgenomics.com
Fabric Genomics is making precision medicine a reality by facilitating clinical labs, hospital systems, and country-sequencing programs to develop, deploy, and scale genomic testing. Our AI approach to genome interpretation and SOP-based workflows enable rapid generation of physician-ready clinical reports for any genomic test.

Fidelis Research
https://fidelis-research.com/
ilyan.hristov@fidelis-research.com
Bespoke biospecimen collections and R&D support services. Fidelis is specialized in human biospecimen collection and processing, as well as customized R&D support services. We are a trusted partner of global pharma, biotech and research organizations. Fidelis works with a wide network of over 60 collection sites in Europe and we able to conduct projects tailored to your specific needs for fresh or frozen tissue, bone marrow aspirate, PBMCs, BMMCs, plasma, serum or whole blood samples, FFPEs, matched sets and other custom collections. Our inventory comprises banked solid tumor and hematological malignancies samples.

Foundation Medicine, Inc.
http://www.foundationmedicine.com
mmartin@foundationmedicine.com
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. For more information, visit www.FoundationMedicine.com.

Genentech
http://www.gene.com
mojaddam@gene.com
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

GenMark Diagnostics
http://www.genmarkdx.com
info@genmarkdx.com
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. GenMark’s ePlex®: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.

GenomeWeb
http://www.genomeweb.com
abaksh@genomeweb.com
GenomeWeb is an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

GlaxoSmithKline
http://www.gsk.com
GSK Oncology
Who we are
A science-led global healthcare company committed to helping those affected by cancer do more, feel better, live longer. Our work in oncology is focused on maximizing patient survival by delivering transformational medicines.

Hamilton Company
http://hamiltoncompany.com
marketingrequest@hamiltoncompany.com
Hamilton Company specializes in the development, manufacturing and customization of precision measurement devices, automated liquid handling workstations, sample management systems, and OEM solutions. Hamilton offers fully automated solutions for sample preparation, drugs of abuse testing, toxicology, pain management testing, next-generation sequencing (NGS), ELISA, and more.

Hologic
https://www.hologic.com
SalesSupport@hologic.com
An innovative medical technology company primarily focused on improving women’s health and well-being, Hologic enables healthier lives everywhere, every day, with clinical superiority that delivers life-changing diagnostic, detection, surgical and medical aesthetic products rooted in science and driven by technology. Hologic: The Science of Sure in action.

IDbyDNA
http://www.idbydna.com
clientservices@idbydna.com
IDbyDNA is revolutionizing the use of clinical metagenomics to improve health by decoding the unknown. IDbyDNA’s product suite delivers unparalleled data analytics and industry-leading expertise to support medical laboratories with actionable infectious disease testing and pathogen surveillance. By profiling tens of thousands of microorganisms from any specimen with a scalable and intuitive approach, IDbyDNA empowers healthcare providers with greater depth and transparency for better identification of pathogens in order to accelerate triage and treatment and improve public health. For more information, visit http://www.idbydna.com or reach out to us on Twitter, Facebook, LinkedIn, Vimeo or YouTube.
Serving customers in the clinical, research, and applied markets, Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, and beyond. By empowering large-scale analysis of genetic variation and function, Illumina is enabling studies that were not imaginable just a few years ago.

Integrated DNA Technologies

Integrated DNA Technologies (IDT) is the world leader in delivering custom nucleic acid products for life sciences and medical research, serving academic, clinical, biotechnology, pharmaceutical development, and agricultural research communities. IDT product applications include qPCR, gene construction, CRISPR genome editing, next generation sequencing, and functional genomics.

Invivoscribe

Invivoscribe® is an ISO13485 compliant cGMP manufacturer of standardized reagents and bioinformatics software used by LabPMM clinical labs and >700 customers. Products include the FDA-approved LeukoStrat® CDx FLT3 Mutation Assay, RUO, and CE-marked assays for capillary and NGS platforms. Kits, gene panels, and MRD assays (Ig, TCR, FLT3, NPM1) are used to stratify/enroll subjects and track malignancies in clinical trials.

LGC, Biosearch Technologies

Biosearch Technologies is the comprehensive genomics portfolio from LGC, providing products and services for genomic analysis that support mission critical applications in molecular diagnostics. We enable our customers from assay development to commercialisation through our expertise in sample preparation, oligo synthesis, enzymes, and components for PCR and NGS.

Life Magnetics

The next generation of RNA sample preparation is here. Scientists at Life Magnetics have built on the discovery that carbon surfaces have a unique interaction with single stranded nucleic acids like RNA. Life Magnetics company has developed proprietary manufacturing technologies to create carbon surfaces precisely tuned for RNA extraction, with any DNA cotamination. Working with leading researchers, we have shown carbon-based surfaces always deliver superior performance as compared to silica-based columns and beads. Talk to us to learn how carbon-based RNA purification can make a difference in your assay.

Luminex

Luminex Corporation is committed to creating innovative, breakthrough solutions to help our customers improve health and advance science worldwide. Our goal is to transform global healthcare and life science research through the development, manufacturing, and marketing of proprietary instruments and assays that deliver cost-effective, rapid results to clinicians and researchers.

Maine Molecular Quality Controls, Inc.

MMQCI designs and markets unique quality controls for molecular testing for inherited disease, pharmacogenetics and infectious disease. Easy-to-use controls contain multiple targets and can be extracted like patient samples, are non-infectious, stable and provide consistent results. INTROL CF Panel I is the first FDA-cleared quality control for genetic testing. Custom orders are welcome at our cGMP facility in Saco, Maine.

Menarini Silicon Biosystems

A biotech company with a passion to advance healthcare and personalized medicine with its DEPArray™ system and, the CELLSEARCH® Circulating Tumor Cell System - only clinically validated blood test cleared by the FDA for detecting and enumerating CTCs to help manage patients with metastatic breast, prostate, and colorectal cancers.

Merck

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types.
Meridian BioScience Inc.
http://www.meridianbioscience.com
gina.martin@meridianbioscience.com
For more than 40 years, Meridian Bioscience has helped healthcare providers in early diagnosis and proper patient management by providing a line of trusted solutions so that patients can get back to living. The Meridian platforms provide established testing technologies with accurate results. Meridian’s comprehensive line of testing options deliver results with speed, accuracy and simplicity.

MetaSystems Group, Inc.
http://www.metasystems.org
sales@metasystems.org
MetaSystems is a leading manufacturer of genetic imaging (high throughput) slide scanning systems and high quality DNA FISH probes for clinical laboratories. We offer innovative solutions for automated interphase FISH spot counting with RapidScore technology, TissueFISH and TMA analysis in fluorescence and brightfield, pathology whole slide imaging, metaphase search, and automatic karyotyping.

MilliporeSigma
http://mandatories.merckgroup.com
The Life Science business of MilliporeSigma, the U.S. life science business of Merck KGaA, Darmstadt, Germany, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and in vitro diagnostics. We specialize in fully-traceable and supply chain-managed manufacturing processes that are driven by diagnostics specialists dedicated to building sustainable relationships with customers through reliability, transparency, and trust.

Mission Bio
http://missionbio.com
viernes@missionbio.com
Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, plugging seamlessly into existing NGS workflows.

NanoString Technologies
https://www.nanostring.com
info@nanostring.com
NanoString® is a leading provider of life science tools for translational research and diagnostics. Cited in over 2,500 peer-reviewed publications, the nCounter® Analysis System measures gene and protein expression to profile novel biomarkers. The company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

New England Biolabs
http://www.neb.com
goodwin@neb.com
For over 40 years, New England Biolabs, Inc. has led the industry in the supply of molecular biology reagents. In addition to products for genomics, NEB continues to expand its offering into areas related to PCR and qPCR, gene expression, sample preparation for next gen sequencing, synthetic biology, glycomics, and genome editing, epigenetics and RNA analysis.

Novartis Oncology
http://www.novartisoncology.com
Novartis is reimagining medicine to improve people's lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 109,000 people of more than 145 nationalities work at Novartis.

Omega Bio-Tek, Inc.
https://www.omegabiotek.com
tradeshows@omegabiotek.com
Since its founding in 1998, Omega Bio-tek has been at the forefront of nucleic acid purification by offering products for clinical and basic research, biotechnology, and agricultural applications. DNA and RNA extraction is the first step for so many downstream analyses, and our goal is to offer high quality products to help improve your workflows.

Ovation.io
https://www.ovation.io/
dana@ovation.io
Ovation is a scientific data company transforming the way a LIMS supports the critical functions of molecular diagnostic laboratories because it is not enough to just track samples and manage workflows. To be successful, labs have to attend to physicians, patients, sales teams, lab operations, revenue cycle management, and business performance. Ovation is here to help with all of it.

Oxford Gene Technology
http://www.ogt.com
michele.elliot@ogt.com
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading institutions worldwide. Our integrated product portfolio enables accurate identification of variation to facilitate understanding of genetic disease. Visit the OGT booth to learn more about our focus on customized solutions and high-quality Cytocell® FISH probes, SureSeq™ next generation sequencing (NGS) panels, and CytoSure™ array products.
Paragon Genomics, Inc.
http://www.paragongenomics.com
cassie@paragongenomics.com
Paragon Genomics, Inc. specializes in sample preparation for targeted next-generation sequencing (NGS). We develop and commercialize reagents and molecular diagnostic tools for genomic analysis of clinically-relevant samples. Our CleanPlex® and CleanPlex® UMI NGS panels combine superior primer design and innovative library preparation chemistry to eliminate non-specific PCR products, incorporate molecular identifiers, and achieve superior target enrichment and variant detection performance.

PCR Biosystems
https://pcrbio.com
info@pcrbio.com
PCR Biosystems is a UK manufacturer of kits and reagents for molecular biology research and diagnostics. This year has seen our expertise in enzyme development and large-scale production be applied to COVID-19 testing solutions for commercial providers and molecular diagnostic companies around the world. We offer a range of standard and custom solutions including bulk supply of reagents, OEM manufacturing and expert technical support to help you achieve the most from our market-leading reagents. To find out more, come and chat with us online!

PerkinElmer
https://perkinelmer-appliedgenomics.com/
CustomerCareUS@perkinelmer.com
PerkinElmer, Inc. offers automated solutions which improve the efficiency of genomic and proteomics workflows. With our nucleic acid isolation technology, liquid handlers, library preparation kits, automated nucleic acid and protein analysis systems, and solutions for single cell genetic analysis, PerkinElmer is eliminating the challenges associated with genomic and proteomic analysis.

Personal Genome Diagnostics
http://www.pgdx.com
info@pgdx.com
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.

Personalis
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

PierianDx
http://www.pieriandx.com
tsarjantson@pieriandx.com
PierianDx empowers progressive health institutions and diagnostic laboratories to build world-class precision medicine programs. Our industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. We drive the adoption of genomics in clinical care and accelerate the fight against cancer and other diseases. www.pieriandx.com

Pillar Biosciences Inc.
https://www.pillar-biosciences.com
info@pillar-biosciences.com
Pillar Biosciences develops and manufactures targeted next-generation sequencing-based assays and software for NGS laboratories. Utilizing proprietary SLIMamp target enrichment technology and PiVAT bioinformatics pipeline, Pillar offers catalog and custom panels with simplified workflow and robust automatable solutions to deliver highly sensitive results from low input DNA samples including liquid biopsy.

PlexBio Co., Ltd
https://www.plexbio.com/
marketing@plexbio.com
PlexBio’s commitment to cancer discovery and treatment begins with early detection and the identification of precision treatments. Our proprietary cutting-edge multiplexing platform uses patented Precision Image Code(PICode) MicroDisc technology to provide rapid, cost-effective, streamline cancer diagnostics.

Promega Corporation
http://www.promega.com
cynthia.petty@promega.com
Promega is a global leader in providing solutions and technical support to life scientists in academic, industrial and government settings. Promega products are used by life scientists asking fundamental questions about biological processes and those applying their knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.

Purigen Biosystems, Inc.
http://www.purigenbio.com
paul.moon@purigenbio.com
Purigen Biosystems’ transformative platform provides a hands-free solution for extracting, enriching and quantifying DNA and RNA from biological samples. Our proprietary approach uses isotachophoresis (ITP), an electric-field-driven technique for purifying, focusing, and/or separating species. Purigen's system is compatible with a range of samples. This includes mammalian cells, FFPE and FNA tissue biopsies, plasma, blood, and buccal swabs.
QIAGEN
https://www.qiagen.com
customercare-US@QIAGEN.com
QIAGEN is known to more than 500,000 customers around the world for our innovation, engagement, integrity, quality and passion. Our mission is to deliver Sample to Insight solutions enabling QIAGEN customers to unlock valuable molecular insights faster, better and more efficiently – from the raw biological sample to the final interpreted result.

Quantabio
http://www.quantabio.com
Ashley.kraus@quantabio.com
Quantabio is a leading provider of advanced DNA and RNA amplification reagents for the most demanding molecular testing applications in applied, translational and life science research. The Quantabio team leverages decades of experience in developing pioneering amplification technologies to deliver cutting-edge products to researchers focused on critical cloning, PCR, qPCR and Next-Generation Sequencing (NGS) based applications. Based in Beverly, Mass., Quantabio offers a growing portfolio of products through its international sales operations, as well as a global network of distributors and commercial service providers.

Rheonix, Inc.
http://www.rheonix.com
info@rheonix.com
The Rheonix Encompass Optimum™ workstation is a fully automated liquid handling system that now integrates and automates nucleic acid purification and NGS library preparation directly from raw samples, enabling labs to begin same shift sequencing with very limited technician time. Rheonix workstations, technologies, and multiplexed sample-to-answer molecular assays are used throughout the world in clinical, food safety and brewing industries.

CORPORATE PARTNER
Roche
http://www.roche.com
ellen.byrum@roche.com
Roche provides innovative PCR and next generation sequencing-based solutions to empower your lab with flexible, scalable and integrated solutions. Our diverse portfolio for clinical diagnostics and research increases lab productivity and enables faster, more confident clinical decisions in virology, infectious diseases, sexually transmitted infections, women’s health, genomics, and oncology.

SoftGenetics, LLC
http://www.softgenetics.com
info@softgenetics.com
Featuring NextGENe software for analysis of NGS data including Variations – SNVs/Indels/Somatics/Structural/Copy Number and HLA; Genetician Assistant NGS Workbench, a knowledge-base for your samples and variant predictions; GeneMarker software with new Repeat Expansion (HTT, DMPK, ALS...) module; ChimerMarker, Chimerism Analysis software and Mutation Surveyor software for the analysis of Sanger Sequences. SoftGenetics is providing no cost trials of each program.

Sophia Genetics
http://www.sophiagenetics.com
events@sophiagenetics.com
At SOPHIA GENETICS, we believe in building a more sustainable global healthcare system. That’s why we developed SOPHIA AI, the advanced technology for Data-Driven Medicine, enabling healthcare institutions around the world make sense of genomic and radiomic data. By empowering clinical researchers to leverage their expertise and work as a community, we democratize Data-Driven Medicine together.

STEMCELL Technologies, Inc.
https://www.stemcell.com/
info@stemcell.com
STEMCELL Technologies offers cell isolation products to enhance the sensitivity of molecular assays for multiple myeloma, CLL, and other hematological malignancies by enriching for cells of interest. RoboSep™automates immunomagnetic cell separation from whole blood or bone marrow and offers a true walk-away solution. RoboSep™ minimizes sample handling, eliminates cross-contamination, and reduces hands-on time - ideal for busy routine labs. www.robosep.com

Streck
https://www.streck.com/
custserv@streck.com
Streck develops and manufactures hematology, immunology and molecular biology products for clinical and research laboratories. Innovative products include the Zulu RT™, a 20 minute real-time PCR platform; real-time PCR test kits for the detection of Gram-negative Beta-lactamase gene families and PhilisaFAST®, a hot-start PCR enzyme specifically formulated for rapid thermal cycling.

CORPORATE PARTNER
Takeda
https://www.takedaoncology.com/
Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 237-year history. Our mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine. Learn more at www.takedaoncology.com.
Tempus
http://tempus.com
support@tempus.com
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitate discovery, development and delivery of optimized therapeutic options for patients through distinctive solution sets. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

The Jackson Laboratory
http://www.jax.org
orderquest@jax.org
The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center, with facilities in Bar Harbor, ME, Sacramento, CA and a new genomic medicine institute in Farmington, CT. Its mission is to discover precise genomic solutions for disease, empowering the global biomedical community in the shared quest to improve human health.

The Pathologist
https://thepathologist.com/
kevin.odonnell@texerepublishing.com
We are The Pathologist, a global magazine focused on pathology and laboratory medicine. We feature articles on all aspects of the field – news, views, personal profiles, practical tips and tricks, new and upcoming developments, training, education, and career development.

Twist Bioscience
http://twistbioscience.com
rmabella@twistbioscience.com
Twist Bioscience, the leader in synthetic DNA with unparalleled precision at scale, is redefining targeted sequencing performance with superior NGS target enrichment solutions. Whether you need library preparation and enrichment components or specific custom panels, Twist can help you achieve higher depth of coverage across target regions with uncompromising quality.

Vela Diagnostics
http://www.veladx.com
rachel.yap@veladx.com
Vela Diagnostics is a leading provider of an automated IVD Next Generation Sequencing (NGS) workflow in the global diagnostics market. Our sample-to-result NGS and real-time PCR solutions standardize testing, improve workflows, and help to reduce cost for optimal efficiency across laboratories of all sizes.

Zymo Research Corp.
http://www.zymoresearch.com
info@zymoresearch.com
Since 1994, Zymo Research has been offering innovative, quality and easy-to-use tools for nucleic acid purification and Epigenetics research. Our innovative products and services simplify complex processes while at the same time improving results. All of our products are supported by unparalleled customer support. Zymo Research – Innovation. Quality. Simplicity.
The 2nd AMP Europe 2021 Congress on Clinical Genomics: Beyond Somatic Mutation, takes place in Milan, Italy from 14 – 16 June, 2021. The Congress will be held in conjunction with the 35th Congress of the Italian Society of Pathology and Translational Medicine (SIPMeT).

The Congress will bring together a network of molecular professionals and representatives of the diagnostics industry. The aim of the Congress is to educate healthcare practitioners and advance the value of molecular laboratories in providing high quality patient care around the world.

A multi-disciplinary scientific program will showcase molecular technology with clinical applications in oncology (solid tumors, hematopathology), genetics (congenital, heritable), and infectious diseases. Most importantly, there will be an emphasis on modern, user-friendly laboratory analytics supported by informatics tools to facilitate the interpretation of actionable genomic test results.

Join us in Milan!

To gain the latest knowledge in precision medicine and how it directly impacts testing and treatment decisions and engage with other thought leaders in the most talked-about areas of molecular pathology.